<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Opioids for cancer pain ‐ an overview of Cochrane reviews - Wiffen, PJ - 2017 | Cochrane Library</title> <meta content="Opioids for cancer pain ‐ an overview of Cochrane reviews - Wiffen, PJ - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012592.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Opioids for cancer pain ‐ an overview of Cochrane reviews - Wiffen, PJ - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012592.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012592.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Opioids for cancer pain ‐ an overview of Cochrane reviews" name="citation_title"/> <meta content="Philip J Wiffen" name="citation_author"/> <meta content="pwiffen@oxfordsrs.org.uk" name="citation_author_email"/> <meta content="Bee Wee" name="citation_author"/> <meta content="Churchill Hospital" name="citation_author_institution"/> <meta content="Sheena Derry" name="citation_author"/> <meta content="Rae Frances Bell" name="citation_author"/> <meta content="Haukeland University Hospital" name="citation_author_institution"/> <meta content="R Andrew Moore" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD012592.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/07/06" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012592.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012592.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012592.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acetaminophen [administration &amp; dosage, therapeutic use]; Administration, Cutaneous; Administration, Oral; Analgesics, Opioid [administration &amp; dosage, adverse effects, *therapeutic use]; Buprenorphine [administration &amp; dosage, therapeutic use]; Cancer Pain [*drug therapy]; Codeine [administration &amp; dosage, therapeutic use]; Fentanyl [administration &amp; dosage, therapeutic use]; Hydromorphone [administration &amp; dosage, therapeutic use]; Methadone [administration &amp; dosage, therapeutic use]; Oxycodone [administration &amp; dosage, therapeutic use]; Phenols [administration &amp; dosage, therapeutic use]; *Review Literature as Topic; Tapentadol; Tramadol [administration &amp; dosage, therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012592.pub2&amp;doi=10.1002/14651858.CD012592.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012592.pub2&amp;doi=10.1002/14651858.CD012592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012592.pub2&amp;doi=10.1002/14651858.CD012592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012592.pub2&amp;doi=10.1002/14651858.CD012592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012592.pub2&amp;doi=10.1002/14651858.CD012592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012592.pub2&amp;doi=10.1002/14651858.CD012592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012592.pub2&amp;doi=10.1002/14651858.CD012592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012592.pub2&amp;doi=10.1002/14651858.CD012592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012592.pub2&amp;doi=10.1002/14651858.CD012592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012592.pub2&amp;doi=10.1002/14651858.CD012592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012592.pub2&amp;doi=10.1002/14651858.CD012592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012592.pub2&amp;doi=10.1002/14651858.CD012592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012592.pub2&amp;doi=10.1002/14651858.CD012592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012592.pub2&amp;doi=10.1002/14651858.CD012592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012592.pub2&amp;doi=10.1002/14651858.CD012592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012592.pub2&amp;doi=10.1002/14651858.CD012592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012592.pub2&amp;doi=10.1002/14651858.CD012592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012592.pub2&amp;doi=10.1002/14651858.CD012592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012592.pub2&amp;doi=10.1002/14651858.CD012592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012592.pub2&amp;doi=10.1002/14651858.CD012592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012592.pub2&amp;doi=10.1002/14651858.CD012592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012592.pub2&amp;doi=10.1002/14651858.CD012592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012592.pub2&amp;doi=10.1002/14651858.CD012592.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="qy4lqFNF";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012592\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012592\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012592\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012592\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","pl","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012592.pub2",title:"Opioids for cancer pain \\u2010 an overview of Cochrane reviews",firstPublishedDate:"Jul 6, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pain, Palliative and Supportive Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=qy4lqFNF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012592.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012592.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012592.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012592.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012592.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012592.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012592.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012592.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012592.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012592.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012592.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012592.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012592.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012592.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>14139 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012592.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012592.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012592.pub2/full#CD012592-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012592.pub2/full#CD012592-sec-0057"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012592.pub2/full#CD012592-sec-0011"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012592.pub2/full#CD012592-sec-0020"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012592.pub2/full#CD012592-sec-0021"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012592.pub2/full#CD012592-sec-0033"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012592.pub2/full#CD012592-sec-0051"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012592.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012592.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012592.pub2/appendices#CD012592-sec-0069"> Search strategies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012592.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012592.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012592.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012592.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012592.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012592.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012592.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Overview</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Opioids for cancer pain ‐ an overview of Cochrane reviews</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012592.pub2/information#CD012592-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Philip J Wiffen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012592.pub2/information#CD012592-cr-0003">Bee Wee</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012592.pub2/information#CD012592-cr-0004">Sheena Derry</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012592.pub2/information#CD012592-cr-0005">Rae Frances Bell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012592.pub2/information#CD012592-cr-0006">R Andrew Moore</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012592.pub2/information/en#CD012592-sec-0075">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 06 July 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012592.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012592.pub2">https://doi.org/10.1002/14651858.CD012592.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012592-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012592-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012592-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012592-abs-0008">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012592-abs-0001" lang="en"> <section id="CD012592-sec-0001"> <h3 class="title" id="CD012592-sec-0001">Background</h3> <p>Pain is a common symptom with cancer, and 30% to 50% of all people with cancer will experience moderate to severe pain that can have a major negative impact on their quality of life. Opioid (morphine‐like) drugs are commonly used to treat moderate or severe cancer pain, and are recommended for this purpose in the World Health Organization (WHO) pain treatment ladder. The most commonly‐used opioid drugs are buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, tramadol, and tapentadol. </p> </section> <section id="CD012592-sec-0002"> <h3 class="title" id="CD012592-sec-0002">Objectives</h3> <p>To provide an overview of the analgesic efficacy of opioids in cancer pain, and to report on adverse events associated with their use. </p> </section> <section id="CD012592-sec-0003"> <h3 class="title" id="CD012592-sec-0003">Methods</h3> <p>We identified systematic reviews examining any opioid for cancer pain published to 4 May 2017 in the Cochrane Database of Systematic Reviews in the Cochrane Library. The primary outcomes were no or mild pain within 14 days of starting treatment, withdrawals due to adverse events, and serious adverse events. </p> </section> <section id="CD012592-sec-0004"> <h3 class="title" id="CD012592-sec-0004">Main results</h3> <p>We included nine reviews with 152 included studies and 13,524 participants, but because some studies appeared in more than one review the number of unique studies and participants was smaller than this. Most participants had moderate or severe pain associated with a range of different types of cancer. Studies in the reviews typically compared one type of opioid or formulation with either a different formulation of the same opioid, or a different opioid; few included a placebo control. Typically the reviews titrated dose to effect, a balance between pain relief and adverse events. Various routes of administration of opioids were considered in the reviews; oral with most opioids, but transdermal administration with fentanyl, and buprenorphine. No review included studies of subcutaneous opioid administration. Pain outcomes reported were varied and inconsistent. The average size of included studies varied considerably between reviews: studies of older opioids, such as codeine, morphine, and methadone, had low average study sizes while those involving newer drugs tended to have larger study sizes. </p> <p>Six reviews reported a GRADE assessment (buprenorphine, codeine, hydromorphone, methadone, oxycodone, and tramadol), but not necessarily for all comparisons or outcomes. No comparative analyses were possible because there was no consistent placebo or active control. Cohort outcomes for opioids are therefore reported, as absolute numbers or percentages, or both. </p> <p>Reviews on buprenorphine, codeine with or without paracetamol, hydromorphone, methadone, tramadol with or without paracetamol, tapentadol, and oxycodone did not have information about the primary outcome of mild or no pain at 14 days, although that on oxycodone indicated that average pain scores were within that range. Two reviews, on oral morphine and transdermal fentanyl, reported that 96% of 850 participants achieved that goal. </p> <p>Adverse event withdrawal was reported by five reviews, at rates of between 6% and 19%. Participants with at least one adverse event were reported by three reviews, at rates of between 11% and 77%. </p> <p>Our GRADE assessment of evidence quality was very low for all outcomes, because many studies in the reviews were at high risk of bias from several sources, including small study size. </p> </section> <section id="CD012592-sec-0005"> <h3 class="title" id="CD012592-sec-0005">Authors' conclusions</h3> <p>The amount and quality of evidence around the use of opioids for treating cancer pain is disappointingly low, although the evidence we have indicates that around 19 out of 20 people with moderate or severe pain who are given opioids and can tolerate them should have that pain reduced to mild or no pain within 14 days. This accords with the clinical experience in treating many people with cancer pain, but overstates to some extent the effectiveness found for the WHO pain ladder. Most people will experience adverse events, and help may be needed to manage the more common undesirable adverse effects such as constipation and nausea. Perhaps between 1 in 10 and 2 in 10 people treated with opioids will find these adverse events intolerable, leading to a change in treatment. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012592-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012592-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012592-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012592-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012592-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012592-abs-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD012592-abs-0005">Polski</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012592-abs-0003" lang="en"> <h3>Morphine‐like drugs for cancer pain</h3> <p><b>Bottom line</b> </p> <p>In about 19 of 20 people with moderate to severe pain from cancer, morphine‐like drugs (opioids) can probably reduce pain to mild or no pain within 14 days if they can tolerate the side effects. Most people will have side effects, and about 1 in 10 to 2 in 10 will need to change their treatment because of side effects. </p> <p><b>Background</b> </p> <p>One person in two or three who gets cancer will suffer from pain that becomes moderate or severe in intensity. The pain tends to get worse as the cancer progresses. Morphine taken by mouth has been used since the 1950s for controlling cancer pain. In 1986 the World Health Organization (WHO) recommended taking morphine‐like drugs for moderate to severe pain from cancer. A number of different drugs are available, some taken by mouth, but others applied in stick‐on patches. </p> <p><b>Study characteristics</b> </p> <p>In this overview of Cochrane Reviews we examined all the evidence on how well morphine‐like drugs worked, mostly when taken by mouth or through a skin patch, how many people had side effects, and how severe or troublesome those side effects were — for example, whether they caused participants to stop taking their medicines. </p> <p>In May 2017, we found nine reviews with 152 included studies and 13,524 participants. The studies were often small, and compared many different preparations. They used different study designs and different ways of showing their pain results. Outcomes of importance to people with cancer pain were often not reported. </p> <p><b>Key findings</b> </p> <p>For two drugs (morphine by mouth and fentanyl patches) more than 19 in 20 people had pain that went from moderate or severe before taking morphine‐like drugs, to pain that was no worse than mild within 14 days if they can tolerate the side effects. Most people taking a morphine‐like drug had at least one side effect. Only about 1 person in 10 to 2 people in 10 stopped taking it because of side effects. The most common side effects were constipation, and nausea and vomiting. </p> <p><b>Quality of the evidence</b> </p> <p>At one level these are encouraging results, and generally agree with surveys of how well the WHO advice works in cancer pain. On another level, the quality of studies in the reviews was generally poor. We would like better study design, and especially better study reporting, which should include the outcome of pain reduced to a level where people with cancer can cope with it (no pain or mild pain). </p> <p>We found that the Cochrane Reviews were of high quality.</p> <p>We rated the quality of the evidence from studies using four levels: very low, low, moderate, or high. Very low quality evidence means that we are very uncertain about the results. High‐quality evidence means that we are very confident in the results. We rated the evidence in the reviews as very low quality. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012592-sec-0057" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012592-sec-0057"></div> <section id="CD012592-sec-0058"> <p> <h5 class="title">Implications for practice</h5> <section id="CD012592-sec-0059"> <section id="CD012592-sec-0060"> <p><b>For people with cancer pain</b></p> <p>The amount and quality of evidence around the use of opioids for treating cancer pain is disappointingly low, although the evidence we have is that around 19 out of 20 people with moderate or severe pain who are given opioids and are able to tolerate them should have that pain reduced to mild or no pain within 14 days. This accords with the clinical experience in treating many people with cancer pain over many years. Most people will experience adverse events, and help may be needed to manage the more common undesirable adverse effects such as constipation and nausea. Perhaps 1 in 10 people treated with opioids will find these adverse events intolerable, leading to a change in treatment. </p> </section> <section id="CD012592-sec-0061"> <p><b>For clinicians</b></p> <p>The amount and quality of evidence around the use of opioids for cancer pain is low. But around 95% of people with moderate or severe pain should be able to titrate to no or only mild pain within 14 days (<a href="./references#CD012592-bbs2-0008" title="WiffenPJ , WeeB , MooreRA . Oral morphine for cancer pain. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003868.pub4] ">Wiffen 2016</a>). This is a clinically important treatment goal judged to be valuable by patients, and probably with economic benefits to health services. Adverse events will be common, but withdrawals due to adverse events uncommon. Oral morphine remains the gold standard for treating moderate to severe cancer pain. </p> </section> <section id="CD012592-sec-0062"> <p><b>For policy makers</b></p> <p>The amount and quality of evidence around the use of opioids for cancer pain is low. But around 95% of people with moderate or severe pain should be able to titrate to no or only mild pain within 14 days (<a href="./references#CD012592-bbs2-0008" title="WiffenPJ , WeeB , MooreRA . Oral morphine for cancer pain. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003868.pub4] ">Wiffen 2016</a>). This is a clinically important treatment goal judged to be valuable by patients, and probably with economic benefits to health services. Adverse events will be common, but withdrawals due to adverse events uncommon. Oral morphine remains the gold standard for treating moderate to severe cancer pain. The WHO ladder has strong opioids as the top rung of the ladder, and the evidence we have, such as it is, supports that position; the WHO ladder is under review at the time of writing. We suggest that policy makers have a duty to ensure that opioids such as morphine are available to all who need them for treating cancer pain. </p> </section> <section id="CD012592-sec-0063"> <p><b>For funders</b></p> <p>This review demonstrates that it is possible to titrate with oral morphine of any formulation, and to be confident that most patients will achieve a high level of pain relief within two weeks. There is likely to be a small number of patients who do not benefit from morphine, or who may develop intolerable adverse events, so other opioids need to be included in formularies. Oral morphine remains the gold standard for treating moderate to severe pain. The WHO ladder has strong opioids as the top rung of the ladder, and the evidence we have, such as it is, supports that position. </p> <p>Opioids are tried and tested for the treatment of cancer pain. Morphine remains the first line treatment in guidelines and textbooks, although oxycodone is the major opioid in the USA. Fentanyl as a transdermal patch is widely used in higher income countries and may cause less constipation than oral opioids. Codeine has no proven role from clinical trial data in treating cancer pain. </p> </section> </section> </p> <p> <h5 class="title">Implications for research</h5> <section id="CD012592-sec-0064"> <section id="CD012592-sec-0065"> <p><b>General</b></p> <p>The reviews on opioids for cancer pain reveal some major problems with our evidence. The WHO pain ladder is now over 30 years old, and remains probably the most‐used and best‐understood pain guidance worldwide. Despite its obvious importance there are few studies that clearly demonstrate how best to perform a study on the most important top rung relating to the treatment of moderate to severe pain. </p> <p>Relatively few reviews were able to obtain data from studies that would be useful in clinical practice, namely the proportion of people with cancer having no or only mild pain within a relatively short time, for example one week after starting treatment. Many individual studies reported statistical outcomes only, rather than absolute pain intensity values. And even when absolute pain intensity values were given, they were often given as average values, rather than in terms of the number who achieved a useful degree of pain relief. </p> <p>Given that many of the better‐quality studies in this review were completed within the last 20 years, the obvious implication for research is to instigate an opioid trialists' collaboration in order to undertake retrospective analyses of clinical trial data, using outcomes of clear patient benefit (no worse than mild pain within two weeks of starting opioid titration), and time taken to achieve that benefit. Trialist collaborations have proved highly informative, with the Antiplatelet Trialists' Collaboration probably the largest example of how retrospective pooling and analysis of clinical trial data can lead to improvements in treatment. </p> </section> <section id="CD012592-sec-0066"> <p><b>Design</b></p> <p>Several methodological issues stand out.</p> <p>The first is the use of outcomes of value to people with cancer pain. Existing trials are designed more for purposes of registration and marketing than informing and improving clinical practice, often because the outcomes chosen are average pain scores, or statistical differences, and rarely how many individuals achieve satisfactory pain relief. </p> <p>The second is the time taken to achieve good pain relief. Some of the reviews — but not individual trials — have defined this as no worse than mild pain within 14 days. This allows for the needs of a titrating dose, but is within a reasonable time. Some might argue that seven days or less would be preferable, but the fact is that we do not have the data available to investigate this point, even though several better‐quality and more modern studies may well have the measurements needed to elucidate it. </p> <p>The third is design. Many studies had a cross‐over design; even though some were relatively short there was significant attrition. Parallel group designs may be preferable. </p> <p>The fourth is size. Many of the studies were very small, and, combined with cross‐over design and consequent attrition, ended up reporting on very few participants. Much larger studies of at least several hundred participants are needed. </p> <p>There are some other design issues that might be addressed. Most important might well be a clear decision concerning the gold‐standard treatment comparator. Placebo‐controlled studies in cancer pain are unlikely to be ethically feasible. In that case an effective and commonly‐available therapy is the ideal common comparator in randomised trials. Oral immediate‐release morphine may be that common comparator. Another is the use of prospective cohort studies rather than randomised trials. Studies could incorporate initial randomisation but a pragmatic design in order to provide immediately‐relevant information on effectiveness and costs. Such designs in pain conditions have been published (<a href="./references#CD012592-bbs2-0051" title="MooreRA , DerryS , McQuayHJ , StraubeS , AldingtonD , WiffenP , et al. Clinical effectiveness: an approach to clinical trial design more relevant to clinical practice, acknowledging the importance of individual differences. Pain2010;149(2):173‐6. [DOI: 10.1016/j.pain.2009.08.007] ">Moore 2010</a>). </p> </section> <section id="CD012592-sec-0067"> <p><b>Measurement (endpoints)</b></p> <p>Trials need to consider additional endpoints of no worse than mild pain as well as the impact of opioids on symptoms that raise serious concerns such as consciousness, appetite, and thirst. The choice of measures to be used in cancer pain studies is not necessarily straightforward. </p> </section> </section> </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012592-sec-0011" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012592-sec-0011"></div> <section id="CD012592-sec-0012"> <h3 class="title" id="CD012592-sec-0012">Description of the condition</h3> <p>Cancers are among the leading causes of morbidity and mortality worldwide, with about 14 million new cases and over eight million deaths annually — approximately 13% of deaths worldwide (<a href="./references#CD012592-bbs2-0041" title="International Agency for Research on Cancer. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. globocan.iarc.fr/Pages/fact_sheets_cancer.aspx (accessed 10 April 2017). ">IARC 2012</a>; <a href="./references#CD012592-bbs2-0073" title="StewartBW , WildCP . World Cancer Report 2014. Lyon: International Agency for Research on Cancer, 2014. [ISBN: 978‐92‐832‐0443‐5] ">Stewart 2014</a>). Globally, 32 million people are living with cancer. In the UK alone in 2014, there were around 350,000 new cases of cancer annually, with around 50% of people surviving for 10 years or more after diagnosis (<a href="./references#CD012592-bbs2-0022" title="Cancer Research UK. Cancer Statistics for the UK. www.cancerresearchuk.org/health‐professional/cancer‐statistics (accessed 10 April 2017). ">CRUK 2014</a>). </p> <p>Cancer pain is perhaps one of the most feared symptoms associated with the disease. Pain may be the first symptom to cause someone to seek medical advice that leads to a diagnosis of cancer, and 30% to 50% of all people with cancer will experience moderate to severe pain (<a href="./references#CD012592-bbs2-0062" title="PortenoyRK , LesageP . Management of cancer pain. Lancet1999;353(9165):1695‐700. [DOI: 10.1016/S0140‐6736(99)01310‐0] ">Portenoy 1999</a>). Pain can occur at any time as the disease progresses but the frequency and intensity of pain tends to increase as the cancer advances (<a href="./references#CD012592-bbs2-0062" title="PortenoyRK , LesageP . Management of cancer pain. Lancet1999;353(9165):1695‐700. [DOI: 10.1016/S0140‐6736(99)01310‐0] ">Portenoy 1999</a>; <a href="./references#CD012592-bbs2-0077" title="van denBeuken‐van EverdingenMH , HochstenbachLM , JoostenEA , Tjan‐HeijnenVC , JanssenDJ . Update on prevalence of pain in patients with cancer: systematic review and meta‐analysis. Journal of Pain and Symptom Management2016;51(6):1070‐90. [DOI: 10.1016/j.jpainsymman.2015.12.340] ">van den Beuken‐van Everdingen 2016</a>). A systematic review published in 2016 has shown that approximately 40% of patients suffered pain after curative treatment, 55% during cancer treatment, and 66% in advanced disease (<a href="./references#CD012592-bbs2-0077" title="van denBeuken‐van EverdingenMH , HochstenbachLM , JoostenEA , Tjan‐HeijnenVC , JanssenDJ . Update on prevalence of pain in patients with cancer: systematic review and meta‐analysis. Journal of Pain and Symptom Management2016;51(6):1070‐90. [DOI: 10.1016/j.jpainsymman.2015.12.340] ">van den Beuken‐van Everdingen 2016</a>). </p> <p>Central to cancer pain, and always a consideration when evaluating evidence for treatment, is the recognition that cancer pain is rarely of uniform intensity. It can be episodic (related to or independent from inciting events/incident pain), with no pain in between or with lesser background pain. The term 'breakthrough pain' is debated (<a href="./references#CD012592-bbs2-0046" title="MercadanteS , MarchettiP , CuomoA , MammucariM , CaraceniA , IOPS MS study Group. Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group. Supportive Care in Cancer2016;24(2):961‐8. [DOI: 10.1007/s00520‐015‐2951‐y] ">Mercadante 2016</a>); there is a literature on opioids for breakthrough pain, though that is not a subject for this overview. Schemes used for titration or initiation of pain relief differ from those used for maintenance; these are considered separately in cancer pain guidelines, and are not specifically the target of this review. </p> <p>Pain related to cancer is described as distressing or intolerable by more than one third of patients (<a href="./references#CD012592-bbs2-0014" title="BreivikH , ChernyN , CollettB , deConnoF , FilbetM , FoubertAJ , et al. Cancer‐related pain: a pan‐European survey of prevalence, treatment, and patient attitudes. Annals of Oncology2009;20(8):1420‐33. [DOI: 10.1093/annonc/mdp001] ">Breivik 2009</a>; <a href="./references#CD012592-bbs2-0077" title="van denBeuken‐van EverdingenMH , HochstenbachLM , JoostenEA , Tjan‐HeijnenVC , JanssenDJ . Update on prevalence of pain in patients with cancer: systematic review and meta‐analysis. Journal of Pain and Symptom Management2016;51(6):1070‐90. [DOI: 10.1016/j.jpainsymman.2015.12.340] ">van den Beuken‐van Everdingen 2016</a>). For those people with advanced cancer, some 75% to 90% will experience pain that has a major impact on daily living (<a href="./references#CD012592-bbs2-0077" title="van denBeuken‐van EverdingenMH , HochstenbachLM , JoostenEA , Tjan‐HeijnenVC , JanssenDJ . Update on prevalence of pain in patients with cancer: systematic review and meta‐analysis. Journal of Pain and Symptom Management2016;51(6):1070‐90. [DOI: 10.1016/j.jpainsymman.2015.12.340] ">van den Beuken‐van Everdingen 2016</a>). Pain had a significant negative correlation with quality of life in people with cancer, for example patients in China, Palestine, and Japan (<a href="./references#CD012592-bbs2-0026" title="DengD , FuL , ZhaoYX , WuX , ZhangG , LiangC , et al. The relationship between cancer pain and quality of life in patients newly admitted to Wuhan Hospice Center of China. American Journal of Hospice &amp; Palliative Care2012;29(1):53‐9. [DOI: 10.1177/1049909111418636] ">Deng 2012</a>; <a href="./references#CD012592-bbs2-0028" title="DreidiMM , Hamdan‐MansourAM . Pain, sleep disturbance, and quality of life among Palestinian patients diagnosed with cancer. Journal of Cancer Education2016;31(4):796‐803. [DOI: 10.1007/s13187‐015‐0946‐5] ">Dreidi 2016</a>; <a href="./references#CD012592-bbs2-0048" title="MikanF , WadaM , YamadaM , TakahashiA , OnishiH , IshidaM , et al. The association between pain and quality of life for patients with cancer in an outpatient clinic, an inpatient oncology ward, and inpatient palliative care units. American Journal of Hospice &amp; Palliative Care2016;33(8):782‐90. [DOI: 10.1177/1049909116630266] ">Mikan 2016</a>), as is true generally with pain (<a href="./references#CD012592-bbs2-0053" title="MooreRA , DerryS , TaylorRS , StraubeS , PhillipsCJ . The costs and consequences of adequately managed chronic non‐cancer pain and chronic neuropathic pain. Pain Practice2014;14(1):79‐94. [DOI: 10.1111/papr.12050] ">Moore 2014</a>). Significant relief of pain to a level equivalent to no pain or only mild pain is generally regarded as an important target for most people with pain (<a href="./references#CD012592-bbs2-0052" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut‐offs ‐ 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400‐12. [DOI: 10.1111/anae.12148] ">Moore 2013</a>). </p> <p>Cancer pain can be the result of the cancer itself, interventions to treat the cancer, and sometimes other underlying pains. Prevalence is also linked to cancer type, with head and neck cancer showing the highest prevalence. Age also has an impact, with younger patients experiencing more pain (<a href="./references#CD012592-bbs2-0063" title="PrommerEE . Pharmacological Management of Cancer‐Related Pain. Cancer Control2015;22(4):412‐25. [PUBMED: 26678968] ">Prommer 2015</a>). For the purposes of this overview review we will focus on the use of opioids for the treatment of pain associated with active cancer in adults where the pain is thought to be associated with the cancer or its treatment. </p> <p>Separate reviews on paracetamol and NSAIDs (<a href="./references#CD012592-bbs2-0027" title="DerryS , WiffenPJ , MooreRA , McNicolED , BellRF , CarrDB , et al. Oral nonsteroidal anti‐inflammatory drugs (NSAIDs) for cancer pain in adults. Cochrane Database of Systematic Reviews2017, Issue 4. [DOI: 10.1002/14651858.CD012638] ">Derry 2017</a>; <a href="./references#CD012592-bbs2-0081" title="WiffenPJ , DerryS , MooreRA , McNicolED , BellRF , CarrDB , et al. Oral paracetamol (acetaminophen) for cancer pain. Cochrane Database of Systematic Reviews2017, Issue 4. [DOI: 10.1002/14651858.CD012637] ">Wiffen 2017a</a>), and a separate review of opioids in cancer pain in children, are underway (<a href="./references#CD012592-bbs2-0082" title="WiffenPJ , CooperTE , AndersonAK , GrayAL , GrégoireMC , LjungmanG , et al. Opioids for cancer‐related pain in children and adolescents. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.CD012564] ">Wiffen 2017b</a>). </p> </section> <section id="CD012592-sec-0013"> <h3 class="title" id="CD012592-sec-0013">Description of the interventions</h3> <p>Opioid analgesics, including codeine, play a significant role in major guidelines associated with the management of pain for patients diagnosed with cancer (<a href="./references#CD012592-bbs2-0016" title="CaraceniA , HanksG , KaasaS , BennettM , BrunelliC , ChernyN , et al. for the European Palliative Research Collaborative (EPCRC), on behalf of the European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence‐based recommendations from the EAPC. Lancet Oncology2012;13(2):e58‐68. [DOI: 10.1016/S1470‐2045(12)70040‐2] ">Caraceni 2012</a>; <a href="./references#CD012592-bbs2-0042" title="JacoxA , CarrDB , PayneR , BerdeCB , BrietbartW , CainJM , et al. Management of Cancer Pain. Clinical Practice Guideline No. 9. AHCPR Publication No. 94‐0592. Rockville, MD: Agency for Health Care Policy and Research, U.S. Department of Health and Human Services, Public Health Service, 1994. ">Jacox 1994</a>; <a href="./references#CD012592-bbs2-0047" title="MiaskowskiC , ClearyJ , BurneyR , CoyneP , FinleyR , FosterR , et al. Guideline for the Management of Cancer Pain in Adults and Children, APS Clinical Practice Guideline Series, No. 3. Glenview, IL: American Pain Society, 2005. ">Miaskowski 2005</a>; <a href="./references#CD012592-bbs2-0057" title="National Institute for Health and Care Excellence. Palliative care for adults: strong opioids for pain relief. Guideline CG140. www.nice.org.uk/guidance/cg140 2016 (accessed 10 April 2017). ">NICE 2016</a>; <a href="./references#CD012592-bbs2-0065" title="RipamontiCI , SantiniD , MaranzanoE , BertiM , RoilaF , ESMO Guidelines Working Group. Management of cancer pain: ESMO Clinical Practice Guidelines. Annals of Oncology2012;23 (Suppl 7):vii139‐54. [DOI: 10.1093/annonc/mds233] ">Ripamonti 2012a</a>; <a href="./references#CD012592-bbs2-0071" title="Scottish Intercollegiate Guidelines Network. Control of pain in adults with cancer. A national clinical guideline. www.sign.ac.uk/pdf/SIGN106.pdf (accessed 10 April 2017). Edinburgh: Scottish Intercollegiate Guidelines Network, 2008. ">SIGN 2008</a>; <a href="./references#CD012592-bbs2-0079" title="World Health Organization. WHO Cancer Pain Relief ‐ a Guide to Opioid Availability, 2nd Edition. apps.who.int/iris/bitstream/10665/37896/1/9241544821.pdf (accessed 10 April 2017)1996. ">WHO 1996</a>). </p> <p>Opioids are used to manage moderate to severe pain. Morphine is the oldest drug in the class of opioids and is still generally considered to be the gold standard. Many other opioids are comparable to morphine in terms of analgesia and also adverse effects. Codeine is considerably less potent than morphine and recommended for mild to moderate cancer pain. The majority of opioids are administered orally, often in the form of modified‐release formulations to reduce dosing to once or twice daily. Rectal administration is also possible. Fentanyl and buprenorphine can also be administered by transdermal patch. Some opioids are suitable for parenteral administration, but this review will not specifically consider this route of administration. </p> <p>Over 16 million prescriptions for potent opioids are prescribed in primary care and dispensed in England each year (<a href="./references#CD012592-bbs2-0061" title="Prescribing &amp; Medicines Team. Prescription Cost Analysis England 2016. Health and Social Care Information Centre2017 (April). [ISBN: 978‐1‐78386‐680‐9] ">PCA 2016</a>), though only about 13% are for cancer pain (<a href="./references#CD012592-bbs2-0084" title="ZinCS , ChenLC , KnaggsRD . Changes in trends and pattern of strong opioid prescribing in primary care. European Journal of Pain (London, England)2014;18(9):1343‐51. [DOI: 10.1002/j.1532‐2149.2014.496.x] ">Zin 2014</a>). The numbers of prescriptions (excluding codeine which is widely used in mild to moderate pain) are as follows: tramadol 7.3 million, morphine 4.8 million, buprenorphine 2.1 million, oxycodone 1.5 million, fentanyl 1.2 million, tapentadol 115,000, methadone 56,000 and hydromorphone 9000. It should be noted that tramadol and buprenorphine are widely used for treatments other than cancer pain. The highest proportion of cancer patients was prescribed low opioid doses (oral morphine equivalents ≤ 50 mg/day; 40%), followed by the dose ranks of 51 mg/day to 100 mg/day (28%), 101 mg/day to 200 mg/day (19%), and more than 200 mg/day (12%) (<a href="./references#CD012592-bbs2-0084" title="ZinCS , ChenLC , KnaggsRD . Changes in trends and pattern of strong opioid prescribing in primary care. European Journal of Pain (London, England)2014;18(9):1343‐51. [DOI: 10.1002/j.1532‐2149.2014.496.x] ">Zin 2014</a>). </p> <p>Morphine and codeine are the two opioids included in the World Health Organization (WHO) essential drugs list (<a href="./references#CD012592-bbs2-0080" title="World Health Organization. WHO Essential Medicines List. 17th list. apps.who.int/iris/bitstream/10665/70640/1/a95053_eng.pdf (accessed 10 April 2017)2011. ">WHO 2011</a>); other opioids are generally similar, but have differences in potency, lipophilicity (the ability of a chemical compound to dissolve in fats, oils, lipids), and routes of administration. These can be important in certain circumstances. All opioids were eligible for inclusion in this overview, but details are given for morphine and codeine as examples in this background description. </p> <section id="CD012592-sec-0014"> <h4 class="title">Morphine</h4> <p>Morphine in one form or another has been available for centuries, and appeared in Pliny's <i>Historia Naturalis</i> (77 AD) as opium, the resin derived from poppy sap. Morphine was extracted from opium in 1803 and named as such by Sertürner, a German pharmacist from Einbeck, in 1817 (<a href="./references#CD012592-bbs2-0064" title="ReyR . History of Pain. Paris: Editions La Decouverte, 1993. [ISBN: 2‐7071‐2256‐4] ">Rey 1993</a>). Oral morphine was first recommended for the treatment of cancer pain in England in the 1950s. This was often in the form of the so‐called 'Brompton cocktail', containing cocaine and alcohol in addition to morphine or diamorphine. Treatment moved towards oral morphine alone as morphine demonstrated effective pain relief without the side effects linked to the 'cocktail'. </p> <p>Following the publication of WHO guidelines in the mid‐1980s, the oral administration of aqueous morphine solution every four hours by the clock became commonplace for moderate to severe cancer pain (<a href="./references#CD012592-bbs2-0078" title="World Health Organization. Cancer Pain Relief. apps.who.int/iris/bitstream/10665/43944/1/9241561009_eng.pdf (accessed 10 April 2017)1986. ">WHO 1986</a>). Morphine in a modified‐release tablet was first marketed around the same time, allowing the dosage interval to be extended to 12 hours. </p> <p>The wide range of formulations and dosages allows great flexibility in the management of severe pain (<a href="./references#CD012592-bbs2-0036" title="Grahame‐SmithDG , AronsonJK . Oxford Textbook of Clinical Pharmacology and Drug Therapy. 3rd Edition. Oxford: Oxford University Press, 2002. [ISBN: 978‐0192632340] ">Grahame‐Smith 2002</a>). Potent opioid analgesics are particularly indicated for the relief of pain in malignant disease and often have the additional very useful actions of relieving anxiety, producing drowsiness, and allowing sleep (<a href="./references#CD012592-bbs2-0036" title="Grahame‐SmithDG , AronsonJK . Oxford Textbook of Clinical Pharmacology and Drug Therapy. 3rd Edition. Oxford: Oxford University Press, 2002. [ISBN: 978‐0192632340] ">Grahame‐Smith 2002</a>). However, all opioid analgesics have the potential to produce adverse events: respiratory depression, nausea and vomiting, constipation, increased pain sensitivity (hyperalgesia), excessive drowsiness, and itching; and morphine can also produce memory loss, nightmares and myoclonic jerks. During chronic opioid therapy, larger doses may be required to sustain the analgesic effect (tolerance) and people can be at risk of opioid withdrawal syndrome upon sudden cessation of the opioid or administration of an antagonist (physiological dependence). </p> <p>This overview will not consider evidence relating to opioid combinations, for which it is known that there is only a small amount of weak evidence (<a href="./references#CD012592-bbs2-0031" title="FallonMT , LairdBJ . A systematic review of combination step III opioid therapy in cancer pain: an EPCRC opioid guideline project. Palliative Medicine2011;25(5):597‐603. [DOI: 10.1177/0269216310392101] ">Fallon 2011</a>). </p> </section> <section id="CD012592-sec-0015"> <h4 class="title">Codeine</h4> <p>Guidelines generally recommend codeine as an analgesic for moderate pain or for situations where simple analgesics (for example, nonsteroidal anti‐inflammatory drugs (NSAIDs) or paracetamol) alone are ineffective or provide suboptimal analgesia. Codeine is the most widely used, naturally occurring narcotic in medical treatment in the world (<a href="./references#CD012592-bbs2-0059" title="Anon . Codeine. www.opiates.com/codeine/ (accessed 10 April 2017)2013. ">Opiates 2013</a>). Codeine can also be synthesised from morphine. It is most commonly administered by mouth (as tablets or syrup), but is also available for intramuscular and subcutaneous injections, and in some countries as suppositories. In many countries it is a controlled substance. </p> <p>In some clinical guidelines, codeine is referred to as a 'weak' opioid analgesic. Codeine and tramadol are defined as step II opioids on the WHO analgesic ladder. The role and utility of step II opioids in cancer pain are controversial (<a href="./references#CD012592-bbs2-0066" title="RipamontiCI . Pain management. Annals of Oncology2012;23 (Suppl 10):x294‐x301. [DOI: 10.1093/annonc/mds360] ">Ripamonti 2012b</a>), and there is currently a discussion as to whether step II opioids should be omitted from the ladder since low doses of step III opioids are equally effective — or in the case of 'poor metabolisers', more effective. The European Association for Palliative Care currently recommends both options (<a href="./references#CD012592-bbs2-0016" title="CaraceniA , HanksG , KaasaS , BennettM , BrunelliC , ChernyN , et al. for the European Palliative Research Collaborative (EPCRC), on behalf of the European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence‐based recommendations from the EAPC. Lancet Oncology2012;13(2):e58‐68. [DOI: 10.1016/S1470‐2045(12)70040‐2] ">Caraceni 2012</a>). </p> </section> </section> <section id="CD012592-sec-0016"> <h3 class="title" id="CD012592-sec-0016">How the intervention might work</h3> <p>Morphine is known to bind to opioid receptors to produce pain relief (<a href="./references#CD012592-bbs2-0045" title="MandalA . Morphine pharmacology. www.news‐medical.net/health/Morphine‐Pharmacology.aspx (accessed 10 April 2017)Last updated 2013. ">Mandal 2013</a>). Three different receptors have been identified. </p> <p> <ol id="CD012592-list-0001"> <li> <p>Mu receptors (subdivided into μ1, μ2, and μ3). These are found in the brainstem and the thalamus. Activation can result in pain relief, sedation, and euphoria, and can also lead to respiratory depression, constipation, and physical dependence. </p> </li> <li> <p>Kappa receptor. This is found in the limbic system, the brain stem, and spinal cord. Activation can result in pain relief, sedation, breathlessness, dysphoria (a state of unease or dissatisfaction), and dependence. </p> </li> <li> <p>Delta receptor. This is found in the brain, spinal cord, and digestive tract. Activation can result in analgesic as well as antidepressant effects. It can also lead to respiratory depression. </p> </li> </ol> </p> <p>The majority of opioids are metabolised by the liver and this can lead to poor or extensive metabolisers, which affects the analgesia experienced by users. The most affected drugs are codeine and tramadol. </p> <section id="CD012592-sec-0017"> <h4 class="title">Morphine</h4> <p>The analgesic effect of morphine is due to its action on the mu opioid receptor. Morphine is metabolised in the liver and brain, the predominant metabolites being morphine‐3‐glucuronide and morphine‐6‐glucuronide. The total production of morphine‐3‐glucuronide is approximately five times higher than that of morphine‐6‐glucuronide. Morphine‐3‐glucuronide has low potency at the mu receptor and is considered to be inactive in humans, while morphine‐6‐glucuronide is a mu receptor agonist with analgesic effect and is more potent than morphine (<a href="./references#CD012592-bbs2-0060" title="PaulD , StandiferKM , InturrisiCE , PasternakGW . Pharmacological characterization of morphine‐6 beta‐glucuronide, a very potent morphine metabolite. Journal of Pharmacology and Experimental Therapeutics1989;251(2):477‐83. [PUBMED: 2810109] ">Paul 1989</a>; <a href="./references#CD012592-bbs2-0083" title="WittwerE , KernSE . Role of morphine's metabolites in analgesia: concepts and controversies. AAPS Journal2006;8(2):E348‐52. [DOI: 10.1007/BF02854905] ">Wittwer 2006</a>). </p> <p>Therapeutic concentrations of morphine and morphine‐6‐glucuronide have been suggested (<a href="./references#CD012592-bbs2-0033" title="FauraCC , MooreRA , HorgaJF , HandCW , McQuayHJ . Morphine and morphine‐6‐glucuronide plasma concentrations and effect in cancer pain. Journal of Pain and Symptom Management1996;11(2):95‐102. [DOI: 10.1016/0885‐3924(95)00148‐4] ">Faura 1996</a>), though a systematic review of factors affecting the ratios of morphine and its major metabolites shows some additional complexities (<a href="./references#CD012592-bbs2-0034" title="FauraCC , CollinsSL , MooreRA , McQuayHJ . Systematic review of factors affecting the ratios of morphine and its major metabolites. Pain1998;74(1):43‐53. [DOI: 10.1016/S0304‐3959(97)00142‐5] ">Faura 1998</a>). Peak plasma concentrations after oral administration depend on the formulation used (<a href="./references#CD012592-bbs2-0020" title="CollinsSL , FauraCC , MooreRA , McQuayHJ . Peak plasma concentrations after oral morphine: a systematic review. Journal of Pain and Symptom Management1998;16(6):388‐402. [DOI: 10.1016/S0885‐3924(98)00094‐3] ">Collins 1998</a>). Renal failure can lead to reduced excretion of morphine‐6‐glucuronide and build‐up in the body, necessitating dose adjustments (<a href="./references#CD012592-bbs2-0013" title="BallM , McQuayHJ , MooreRA , AllenMC , FisherA , SearJ . Renal failure and the use of morphine in intensive care. Lancet1985;1(8432):784‐6. [DOI: 10.1016/S0140‐6736(85)91448‐5] ">Ball 1985</a>; <a href="./references#CD012592-bbs2-0068" title="SearJ , MooreA , HunnisetA , BaldwinD , AllenM , HandC , et al. Morphine kinetics and kidney transplantation: morphine removal is influenced by renal ischemia. Anesthesia and Analgesia1985;64(11):1065‐70. [PUBMED: 3901820] ">Sear 1985</a>; <a href="./references#CD012592-bbs2-0069" title="SearJW , HandCW , MooreRA , McQuayHJ . Studies on morphine disposition: influence of renal failure on the kinetics of morphine and its metabolites. British Journal of Anaesthesia1989;62(1):28‐32. [DOI: 10.1093/bja/62.1.22] ">Sear 1989</a>), though alternative drugs such as fentanyl or oxycodone are often used instead where renal problems may be present, since these alternatives to morphine are far less dependent on the kidneys for excretion. </p> </section> <section id="CD012592-sec-0018"> <h4 class="title">Codeine</h4> <p>Codeine is a prodrug that is metabolised to morphine in the liver. In most people, 5% to 10% of codeine is converted to morphine; a 30 mg dose of codeine is considered equivalent to a 3 mg dose of morphine. The ability to metabolise codeine varies between individuals. Some (up to 10% of white people, 2% of Asians, and 1% of Arabs) are 'poor metabolisers' with low rates of conversion (<a href="./references#CD012592-bbs2-0018" title="CascorbiI . Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication. European Journal of Clinical Investigation2003;33 (Suppl 2):17‐22. [PUBMED: 14641552] ">Cascorbi 2003</a>), and in these people codeine is a relatively ineffective analgesic. At the other extreme, a few individuals are 'extensive metabolisers' with high rates of conversion, and this puts them at increased risk of toxicity from standard doses. There are rare case reports of deaths attributed to ultrarapid metabolism of codeine administered at recommended doses (<a href="./references#CD012592-bbs2-0019" title="CiszkowskiC , MadadiP , PhillipsMS , LauwersAE , KorenG . Codeine, ultrarapid‐metabolism genotype, and postoperative death. New England Journal of Medicine2009;361(8):827‐8. [DOI: 10.1056/NEJMc0904266] ">Ciszkowski 2009</a>; <a href="./references#CD012592-bbs2-0044" title="MadadiP , KorenG , CairnsJ , ChitayatD , GaedigkA , LeederJS , et al. Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Canadian Family Physician Medecin de Famille Canadien2007;53(1):33‐5. [PUBMED: 17872605] ">Madadi 2007</a>). </p> <p>A number of medications can interfere with the enzymes that catalyse the metabolism of codeine, and by increasing or decreasing the extent of conversion they can change the analgesic effect. For example the selective serotonin reuptake inhibitors (SSRIs) fluoxetine and paroxetine (used for the treatment of depression which may present as a co‐morbidity along with malignant disease), as well as the serotonin and noradrenaline reuptake inhibitor duloxetine (which may be used for pain management), reduce conversion; and other drugs, such as rifampicin and dexamethasone, increase it. </p> </section> </section> <section id="CD012592-sec-0019"> <h3 class="title" id="CD012592-sec-0019">Why it is important to do this overview</h3> <p>The goal of treatment of cancer pain is to minimise pain in a relatively short period while minimising adverse event severity (<a href="#CD012592-fig-0001">Figure 1</a>). Measurement of pain and assessment of adverse event severity and impact are key to this. Opioids are an important part of managing cancer pain. In many countries, strong opioids such as morphine are severely restricted, if available at all. This leaves many people with cancer at risk of severe pain and suffering. </p> <div class="figure" id="CD012592-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="original image" data-id="CD012592-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012592.pub2/media/CDSR/CD012592/image_n/nCD012592-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <p>Morphine has long been considered the preferred choice of opioid. It is widely, though still not universally, available across the world, is comparatively inexpensive, and is effective orally. It is listed in the WHO essential medicines list (<a href="./references#CD012592-bbs2-0080" title="World Health Organization. WHO Essential Medicines List. 17th list. apps.who.int/iris/bitstream/10665/70640/1/a95053_eng.pdf (accessed 10 April 2017)2011. ">WHO 2011</a>). This overview of Cochrane Reviews is important to determine the effectiveness of morphine compared to other interventions used in cancer pain. Codeine is inexpensive and has a long track record of use since the late 1800s. However, there is an ongoing controversy as to whether there is a place for step II opioids such as tramadol and codeine in the treatment of cancer pain. </p> <p>This overview provides a summary of the evidence for the majority of opioid medicines available internationally and covers those on the WHO essential medicines list, namely codeine and morphine. This review will inform policy makers such as the WHO on the evidence for analgesic efficacy and adverse effects of opioids to treat cancer‐related pain. </p> <p>There are also fears regarding implementing and prescribing opioids. Clinicians might be reassured regarding the safety profile and effectiveness of opioids, and that should lead to improved pain management and treatment earlier in cancer, alongside Cochrane Reviews on paracetamol and NSAIDs (<a href="./references#CD012592-bbs2-0027" title="DerryS , WiffenPJ , MooreRA , McNicolED , BellRF , CarrDB , et al. Oral nonsteroidal anti‐inflammatory drugs (NSAIDs) for cancer pain in adults. Cochrane Database of Systematic Reviews2017, Issue 4. [DOI: 10.1002/14651858.CD012638] ">Derry 2017</a>; <a href="./references#CD012592-bbs2-0081" title="WiffenPJ , DerryS , MooreRA , McNicolED , BellRF , CarrDB , et al. Oral paracetamol (acetaminophen) for cancer pain. Cochrane Database of Systematic Reviews2017, Issue 4. [DOI: 10.1002/14651858.CD012637] ">Wiffen 2017a</a>). People with cancer sometimes feel that a prescription of morphine can signify that they are in the last stages of illness. Reassurance that opioids are not confined to end stage illness could be reassuring. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012592-sec-0020" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012592-sec-0020"></div> <p>To provide an overview of the analgesic efficacy of opioids in cancer pain, and to report on adverse events associated with their use. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012592-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012592-sec-0021"></div> <section id="CD012592-sec-0022"> <h3 class="title">Criteria for considering reviews for inclusion</h3> <p>We included all Cochrane Reviews of randomised, controlled trials (RCTs) of opioid drugs for the treatment of cancer pain in adults. </p> </section> <section id="CD012592-sec-0023"> <h3 class="title">Search methods for identification of reviews</h3> <p>We searched the Cochrane Database of Systematic Reviews (in the Cochrane Library) on 4 May 2017. The search strategy is presented in <a href="./appendices#CD012592-sec-0070">Appendix 1</a>. </p> </section> <section id="CD012592-sec-0024"> <h3 class="title" id="CD012592-sec-0024">Data collection and analysis</h3> <p>Two review authors independently selected reviews for inclusion, carried out assessments of methodological quality, and extracted data. We resolved any disagreements by discussion, involving a third review author when necessary. </p> <section id="CD012592-sec-0025"> <h4 class="title">Selection of reviews</h4> <p>Included reviews assessed RCTs evaluating the effects of an opioid drug given for relief of moderate to severe cancer pain, compared with placebo or a different active treatment, and provided: </p> <p> <ol id="CD012592-list-0002"> <li> <p>details of inclusion and exclusion criteria;</p> </li> <li> <p>details of databases searched and relevant search strategies;</p> </li> <li> <p>patient‐reported pain relief; and</p> </li> <li> <p>summary results for at least one desired outcome.</p> </li> </ol> </p> </section> <section id="CD012592-sec-0026"> <h4 class="title">Data extraction and management</h4> <p>We extracted data from the included reviews using a standard data extraction form, using original study reports only if specific data were missing. </p> <p>We collected information on:</p> <p> <ol id="CD012592-list-0003"> <li> <p>number of included studies and participants;</p> </li> <li> <p>drug, dose, and route of administration;</p> </li> <li> <p>any additional methodological information of potential importance.</p> </li> </ol> </p> <p>We looked for information on risk ratio (RR) and number needed to treat for an additional beneficial outcome (NNT), number needed to treat to prevent an event (NNTp), and number needed to treat for an additional harmful outcome (NNH), or data to calculate these. </p> <section id="CD012592-sec-0027"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD012592-list-0004"> <li> <p>Proportion of participants reporting no worse than mild pain on treatment by 14 days after start of treatment. </p> </li> <li> <p>Patient Global Impression of Change (PGIC) of much or very much improved.</p> </li> <li> <p>Withdrawals due to adverse events.</p> </li> </ol> </p> <p>These outcomes were also extracted when reported as moderate or substantial improvement according to the relevant Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) criteria (<a href="./references#CD012592-bbs2-0029" title="DworkinRH , TurkDC , WyrwichKW , BeatonD , CleelandCS , FarrarJT , et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain2008;9(2):105‐21. [DOI: 10.1016/j.jpain.2007.09.005] ">Dworkin 2008</a>). </p> </section> <section id="CD012592-sec-0028"> <h5 class="title">Secondary outcomes</h5> <p>Description of adverse events including:</p> <p> <ol id="CD012592-list-0005"> <li> <p>withdrawals due to lack of efficacy;</p> </li> <li> <p>participants experiencing any adverse event;</p> </li> <li> <p>participants experiencing any serious adverse event, including death. Serious adverse events typically include any untoward medical occurrence or effect that at any dose results in death, is life‐threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an 'important medical event' that may jeopardise the patient, or may require an intervention to prevent one of the above characteristics or consequences; </p> </li> <li> <p>specific adverse events, such as thirst, reduced appetite, somnolence and dizziness, as reported. </p> </li> </ol> </p> </section> </section> <section id="CD012592-sec-0029"> <h4 class="title">Assessment of methodological quality of included reviews</h4> <section id="CD012592-sec-0030"> <h5 class="title">Quality of included reviews</h5> <p>We assessed each included review to determine if it satisfied the criteria specified in the 'Assessment of Multiple Systematic Reviews' (AMSTAR) measurement tool for rigorous methodological quality (<a href="./references#CD012592-bbs2-0070" title="SheaBJ , GrimshawJM , WellsGA , BoersM , AnderssonN , HamelC , et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Medical Research Methodology2007;7:10. [DOI: 10.1186/1471‐2288‐7‐10] ">Shea 2007</a>). </p> <p>Each review was required to:</p> <p> <ol id="CD012592-list-0006"> <li> <p>provide an a priori design;</p> </li> <li> <p>carry out duplicate study selection and data extraction;</p> </li> <li> <p>carry out a comprehensive literature search;</p> </li> <li> <p>include published and unpublished studies irrespective of language of publication;</p> </li> <li> <p>provide a list of studies (included and excluded);</p> </li> <li> <p>assess and document the scientific quality of the included studies;</p> </li> <li> <p>use the scientific quality of the included studies appropriately in formulating conclusions;</p> </li> <li> <p>use appropriate methods to combine the findings of studies; and</p> </li> <li> <p>state conflicts of interests.</p> </li> </ol> </p> <p>For each review, we planned to assess the likelihood of publication bias by calculating the number of participants in studies with zero effect (RR = 1) that would be needed to give an NNT too high to be clinically relevant (<a href="./references#CD012592-bbs2-0050" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15‐23. [ISBN: 978‐0‐931092‐69‐5] ">Moore 2008</a>). In this case, we used as a cut‐off for clinical relevance an NNT of 10 or above for the outcome of participant‐reported pain relief of 30% or greater. We used this method because statistical tests for presence of publication bias have been shown to be unhelpful (<a href="./references#CD012592-bbs2-0075" title="ThorntonA , LeeP . Publication bias in meta‐analysis: its causes and consequences. Journal of Clinical Epidemiology2000;53(2):207‐16. [DOI: 10.1016/S0895‐4356(99)00161‐4] ">Thornton 2000</a>). </p> </section> </section> <section id="CD012592-sec-0031"> <h4 class="title">Data synthesis</h4> <p>We planned to use information on the selected efficacy outcomes to draw up comparisons of analgesic efficacy, using indirect comparisons of different drugs from almost identical clinical trial conditions, with placebo as a common comparator (<a href="./references#CD012592-bbs2-0035" title="GlennyAM , AltmanDG , SongF , SakarovitchC , DeeksJJ , D'AmicoR , et al. International Stroke Trial Collaborative Group. Indirect comparisons of competing interventions. Health Technology Assessment2005;9(26):1‐134, iii‐iv. [DOI: 10.3310/hta9260] ">Glenny 2005</a>; <a href="./references#CD012592-bbs2-0072" title="SongF , AltmanDG , GlennyAM , DeeksJJ . Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta‐analyses. BMJ2003;326(7387):472. [DOI: 10.1136/bmj.326.7387.472] ">Song 2003</a>). It was known that direct comparison studies were almost completely absent, and probably too small to be of value, but we planned to note any useful observations. </p> <p>Where the selected efficacy outcomes were not provided in an individual review, we planned to calculate them wherever possible from the data provided. We planned no further data synthesis. </p> <p>At least 200 participants had to be available for any outcome before we pooled studies (<a href="./references#CD012592-bbs2-0049" title="MooreRA , GavaghanD , TramèrMR , CollinsSL , McQuayHJ . Size is everything ‐ large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209‐16. [DOI: 10.1016/S0304‐3959(98)00140‐7] ">Moore 1998</a>). Where appropriate we planned to use or calculate RR or risk difference (RD) with 95% confidence intervals (CIs) using a fixed‐effect model (<a href="./references#CD012592-bbs2-0055" title="MorrisJA , GardnerMJ . Calculating confidence intervals for relative risk, odds ratios and standardised ratios and rates. In: GardnerMJ , AltmanDG editor(s). Statistics with Confidence ‐ Confidence Intervals and Statistical Guidelines. London: British Medical Journal, 1995:50‐63. ">Morris 1995</a>). We would have used or calculated NNT and NNH with 95% CIs using the pooled number of events, following the method devised by Cook and Sackett (<a href="./references#CD012592-bbs2-0021" title="CookRJ , SackettDL . The number needed to treat: a clinically useful measure of treatment effect. BMJ (Clinical Research Ed.)1995;310(6977):452‐4. [DOI: 10.1136/bmj.310.6977.452] ">Cook 1995</a>). We would have assumed a statistically significant difference from control when the 95% CI of the RR did not include 1, or 0 for the RD. </p> <p>In the event, no pooled statistical analysis was possible, and we have reported results for individual studies as absolute numbers or percentages where appropriate. </p> <section id="CD012592-sec-0032"> <h5 class="title">Quality of the evidence</h5> <p>We used the GRADE system to assess the quality of the evidence related to the key outcomes, as appropriate (<a href="./appendices#CD012592-sec-0071">Appendix 2</a>). Two review authors independently rated the quality of each outcome independently of any GRADE evaluation in the original reports. </p> <p>We were particularly interested in inconsistency, where point estimates vary widely across studies or CIs of studies show minimal or no overlap (<a href="./references#CD012592-bbs2-0037" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 7. Rating the quality of evidence‐‐inconsistency. Journal of Clinical Epidemiology2011;64(12):1294‐302. [DOI: 10.1016/j.jclinepi.2011.03.017] ">Guyatt 2011</a>), but there were too few data. Small studies have been shown to overestimate treatment effects, probably because the conduct of small studies is more likely to be less rigorous, allowing critical criteria to be compromised (<a href="./references#CD012592-bbs2-0024" title="DechartresA , TrinquartL , BoutronI , RavaudP . Influence of trial sample size on treatment effect estimates: meta‐epidemiological study. BMJ2013;346:f2304. [DOI: 10.1136/bmj.f2304] ">Dechartres 2013</a>; <a href="./references#CD012592-bbs2-0058" title="NüeschE , TrelleS , ReichenbachS , RutjesAW , TschannenB , AltmanDG , et al. Small study effects in meta‐analyses of osteoarthritis trials: meta‐epidemiological study. BMJ2010;341:c3515. [DOI: 10.1136/bmj.c3515] ">Nüesch 2010</a>), and large studies often have smaller treatment effects (<a href="./references#CD012592-bbs2-0025" title="DechartresA , AltmanDG , TrinquartL , BoutronI , RavaudP . Association between analytic strategy and estimates of treatment outcomes in meta‐analyses. JAMA2014;312(6):623‐30. [DOI: 10.1001/jama.2014.8166] ">Dechartres 2014</a>). </p> <p>In addition, there may be circumstances where the overall rating for a particular outcome needs to be adjusted as recommended by GRADE guidelines (<a href="./references#CD012592-bbs2-0038" title="GuyattG , OxmanAD , SultanS , BrozekJ , GlasziouP , Alonso‐CoelloP , et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology2013;66(2):151‐7. [DOI: 10.1016/j.jclinepi.2012.01.006] ">Guyatt 2013a</a>). For example, where there are so few data that the results are highly susceptible to the random play of chance, or if studies use 'last observation carried forward' (LOCF) imputation in circumstances where there are substantial differences in adverse event withdrawals, one can have no confidence in the result, and would need to downgrade the quality of the evidence by three levels, to very low quality. In circumstances where there were no data reported for an outcome, we reported the level of evidence as very low quality (<a href="./references#CD012592-bbs2-0039" title="GuyattGH , OxmanAD , SantessoN , HelfandM , VistG , KunzR , et al. GRADE guidelines: 12. Preparing summary of findings tables‐binary outcomes. Journal of Clinical Epidemiology2013;66(2):158‐72. [DOI: 10.1016/j.jclinepi.2012.01.012] ">Guyatt 2013b</a>). </p> <p>We used the following descriptors for levels of evidence (<a href="./references#CD012592-bbs2-0030" title="Anon . EPOC author resources. epoc.cochrane.org/epoc‐specific‐resources‐review‐authors (accessed 10 April 2017)2015. ">EPOC 2015</a>); substantially different in this context implies a large enough difference that it might affect a decision. </p> <p> <ol id="CD012592-list-0007"> <li> <p><b>High:</b> This research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different is low. </p> </li> <li> <p><b>Moderate:</b> This research provides a good indication of the likely effect. The likelihood that the effect will be substantially different is moderate. </p> </li> <li> <p><b>Low:</b> This research provides some indication of the likely effect. However, the likelihood that it will be substantially different is high. </p> </li> <li> <p><b>Very low:</b> This research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different is very high. </p> </li> </ol> </p> <p>We used the amount and quality of evidence to report results in a hierarchical way, based on the primary outcome of interest, as has been done previously in overview reviews (<a href="./references#CD012592-bbs2-0054" title="MooreRA , DerryS , AldingtonD , WiffenPJ . Single dose oral analgesics for acute postoperative pain in adults ‐ an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2015, Issue 9. [DOI: 10.1002/14651858.CD008659.pub3] ">Moore 2015</a>). We split the available information into five groups, essentially according to the GRADE descriptors. </p> <p> <ol id="CD012592-list-0008"> <li> <p>Drugs and doses for which Cochrane Reviews found no information (very low quality evidence). </p> </li> <li> <p>Drugs and doses for which Cochrane Reviews found inadequate information: fewer than 200 participants in comparisons, in at least two studies (very low quality evidence). </p> </li> <li> <p>Drugs and doses for which Cochrane Reviews found evidence of effect, but where results were potentially subject to publication bias. We planned to calculate the number of additional participants needed in studies with zero effect (RR = 1) to change the NNT for at least 50% maximum pain relief to an unacceptably high level (in this case the arbitrary NNT of 10) (<a href="./references#CD012592-bbs2-0050" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15‐23. [ISBN: 978‐0‐931092‐69‐5] ">Moore 2008</a>). Where this number was less than 400 (equivalent to four studies with 100 participants per comparison, or 50 participants per group), we would consider the results to be susceptible to publication bias and therefore unreliable (low‐quality evidence). In the event, there were insufficient data to do this. </p> </li> <li> <p>Drugs and doses for which Cochrane Reviews found no evidence of effect or evidence of no effect: more than 200 participants in comparisons, but where there was no statistically significant difference from placebo (moderate‐ or high‐quality evidence). </p> </li> <li> <p>Drugs and doses for which Cochrane Reviews found evidence of effect, where results were reliable and not subject to potential publication bias (high‐quality evidence). </p> </li> </ol> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012592-sec-0033" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012592-sec-0033"></div> <section id="CD012592-sec-0034"> <h3 class="title" id="CD012592-sec-0034">Description of included reviews</h3> <p>We included nine reviews (<a href="./references#CD012592-bbs2-0001" title="BaoYJ , HouW , KongXY , YangL , XiaJ , HuaBJ , et al. Hydromorphone for cancer pain. Cochrane Database of Systematic Reviews2016, Issue 10. [DOI: 10.1002/14651858.CD011108.pub2] ">Bao 2016</a>; <a href="./references#CD012592-bbs2-0002" title="HadleyG , DerryS , MooreRA , WiffenPJ . Transdermal fentanyl for cancer pain. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD010270.pub2] ">Hadley 2013</a>; <a href="./references#CD012592-bbs2-0003" title="NicholsonAB , WatsonGR , DerryS , WiffenPJ . Methadone for cancer pain. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.CD003971.pub4] ">Nicholson 2017</a>; <a href="./references#CD012592-bbs2-0004" title="Schmidt‐HansenM , BennettMI , ArnoldS , BromhamN , HilgartJS . Oxycodone for cancer‐related pain. Cochrane Database of Systematic Reviews2015, Issue 2. [DOI: 10.1002/14651858.CD003870.pub5] ">Schmidt‐Hansen 2015a</a>; <a href="./references#CD012592-bbs2-0005" title="Schmidt‐HansenM , BromhamN , TaubertM , ArnoldS , HilgartJS . Buprenorphine for treating cancer pain. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD009596.pub4] ">Schmidt‐Hansen 2015b</a>; <a href="./references#CD012592-bbs2-0006" title="StraubeC , DerryS , JacksonKC , WiffenPJ , BellRF , StrasselsS , et al. Codeine, alone and with paracetamol (acetaminophen), for cancer pain. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD006601.pub4] ">Straube 2014</a>; <a href="./references#CD012592-bbs2-0007" title="WiffenPJ , DerryS , NaessensK , BellRF . Oral tapentadol for cancer pain. Cochrane Database of Systematic Reviews2015, Issue 9. [DOI: 10.1002/14651858.CD011460.pub2] ">Wiffen 2015</a>; <a href="./references#CD012592-bbs2-0008" title="WiffenPJ , WeeB , MooreRA . Oral morphine for cancer pain. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003868.pub4] ">Wiffen 2016</a>; <a href="./references#CD012592-bbs2-0009" title="WiffenPJ , DerryS , MooreRA . Tramadol with or without paracetamol (acetaminophen) for cancer pain. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD012508] ">Wiffen 2017c</a>). Summary table A shows the conditions treated, the opioid used, the routes of administration and the numbers of studies and participants included in the reviews. </p> <p>Most participants had moderate or severe pain associated with a range of different types of cancer. Studies in the reviews typically compared one type of opioid or formulation with either a different formulation of the same opioid, or a different opioid; few included a placebo control. Typically the reviews titrated dose to effect, balancing pain relief with adverse events. Various pain outcomes were used: average pain was reported by some, whilst others reported a 30% or 50% reduction in pain, or combinations of different outcomes. </p> <p>There were 152 included studies and 13,254 participants across all reviews. Some studies were included in more than one review. We excluded one review because it covered only specific adverse effects of certain opioids, did not examine efficacy, and was performed for a specific UK purpose concerning the Liverpool Care Pathway (<a href="./references#CD012592-bbs2-0010" title="WiffenPJ , DerryS , MooreRA . Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain. Cochrane Database of Systematic Reviews2014, Issue 5. [DOI: 10.1002/14651858.CD011056.pub2] ">Wiffen 2014</a>). </p> <p>Some of the 152 included studies had common active comparators; for example, morphine was used as an active comparator in a number of opioid studies. The number of unique studies was probably closer to 120. Various routes of administration of opioids were considered in the reviews: oral with most opioids, but transdermal administration only with fentanyl (<a href="./references#CD012592-bbs2-0002" title="HadleyG , DerryS , MooreRA , WiffenPJ . Transdermal fentanyl for cancer pain. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD010270.pub2] ">Hadley 2013</a>), and various routes with buprenorphine (<a href="./references#CD012592-bbs2-0005" title="Schmidt‐HansenM , BromhamN , TaubertM , ArnoldS , HilgartJS . Buprenorphine for treating cancer pain. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD009596.pub4] ">Schmidt‐Hansen 2015b</a>). </p> <p>Several reviews included a small number of studies and participants, but over 1000 participants were involved in studies with buprenorphine, fentanyl, morphine, oxycodone, and tapentadol. The total number of participants in comparisons was over 13,000, but the number of unique individuals was smaller because some studies included more than one opioid. Most included studies involved head‐to‐head direct comparisons, and few reported comparisons with placebo. </p> <p>The average size of included studies varied considerably between reviews. Older opioids, such as codeine, morphine, and methadone, had low average study sizes of 48, 68, and 64 participants respectively. Those involving newer drugs — such as transdermal fentanyl (average 138 participants per study), oxycodone (115), and oral tapentadol (257) — tended to involve larger studies. Smaller studies pose problems for interpretation (<a href="./references#CD012592-bbs2-0032" title="FanelliD , CostasR , IoannidisJP . Meta‐assessment of bias in science. Proceedings of the National Academy of Sciences of the USA 2017 Mar 20 [Epub ahead of print];114(14):3714‐9. [DOI: 10.1073/pnas.1618569114] ">Fanelli 2017</a>; <a href="./references#CD012592-bbs2-0049" title="MooreRA , GavaghanD , TramèrMR , CollinsSL , McQuayHJ . Size is everything ‐ large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209‐16. [DOI: 10.1016/S0304‐3959(98)00140‐7] ">Moore 1998</a>; <a href="./references#CD012592-bbs2-0056" title="NguyenTL , CollinsGS , LamyA , DevereauxPJ , DaurèsJP , LandaisP , et al. Simple randomization did not protect against bias in smaller trials. Journal of Clinical Epidemiology 2017 Feb 29 [Epub ahead of print];84:105‐13. [DOI: 10.1016/j.jclinepi.2017.02.010] ">Nguyen 2017</a>; <a href="./references#CD012592-bbs2-0074" title="ThorlundK , ImbergerG , WalshM , ChuR , GluudC , WetterslevJ , et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta‐analysis‐‐a simulation study. PLoS One2011;6(10):e25491. [DOI: 10.1371/journal.pone.0025491] ">Thorlund 2011</a>). </p> <p>Six reviews reported a GRADE assessment (buprenorphine, codeine, hydromorphone, methadone, oxycodone, and tramadol) but not necessarily for all comparisons or outcomes. </p> <section id="CD012592-sec-0035"> <h4 class="title">Summary table A: included reviews</h4> <p> <div class="table" id="CD012592-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reference</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Condition treated</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Opioid and means of delivery</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Studies/Participants</b> </p> <p><b>(average participants per study)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0001" title="BaoYJ , HouW , KongXY , YangL , XiaJ , HuaBJ , et al. Hydromorphone for cancer pain. Cochrane Database of Systematic Reviews2016, Issue 10. [DOI: 10.1002/14651858.CD011108.pub2] ">Bao 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe pain – various cancers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydromorphone – oral, normal release and controlled release</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/604 (151)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0002" title="HadleyG , DerryS , MooreRA , WiffenPJ . Transdermal fentanyl for cancer pain. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD010270.pub2] ">Hadley 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe or chronic cancer pain related to variety of cancers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fentanyl – transdermal</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/1244 (138)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0003" title="NicholsonAB , WatsonGR , DerryS , WiffenPJ . Methadone for cancer pain. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.CD003971.pub4] ">Nicholson 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe cancer pain due to advanced or terminal</p> <p>cancer – variety of cancers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methadone – oral, IM</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/388 (64)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0004" title="Schmidt‐HansenM , BennettMI , ArnoldS , BromhamN , HilgartJS . Oxycodone for cancer‐related pain. Cochrane Database of Systematic Reviews2015, Issue 2. [DOI: 10.1002/14651858.CD003870.pub5] ">Schmidt‐Hansen 2015a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cancer‐related pain across a range of malignancies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxycodone – oral, normal release and controlled release, IM and IV</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/2648 (115)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0005" title="Schmidt‐HansenM , BromhamN , TaubertM , ArnoldS , HilgartJS . Buprenorphine for treating cancer pain. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD009596.pub4] ">Schmidt‐Hansen 2015b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe cancer pain related to variety of cancers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Buprenorphine – sub‐lingual, sub‐dermal, transdermal, rectal, epidural, IM, and IV</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/1421 (75)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0006" title="StraubeC , DerryS , JacksonKC , WiffenPJ , BellRF , StrasselsS , et al. Codeine, alone and with paracetamol (acetaminophen), for cancer pain. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD006601.pub4] ">Straube 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe pain – various cancers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Codeine with or without paracetamol – oral, normal release and controlled release, and IM </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/721 (48)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0007" title="WiffenPJ , DerryS , NaessensK , BellRF . Oral tapentadol for cancer pain. Cochrane Database of Systematic Reviews2015, Issue 9. [DOI: 10.1002/14651858.CD011460.pub2] ">Wiffen 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe pain – various cancers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tapentadol – oral</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/1029 (257)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0008" title="WiffenPJ , WeeB , MooreRA . Oral morphine for cancer pain. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003868.pub4] ">Wiffen 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe pain – various cancers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Morphine – oral, instant release and modified release, rectal, epidural</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62/4241 (68)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0009" title="WiffenPJ , DerryS , MooreRA . Tramadol with or without paracetamol (acetaminophen) for cancer pain. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD012508] ">Wiffen 2017c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe pain – various cancers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tramadol with or without paracetamol – oral</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/958 (96)</p> </td> </tr> </tbody> </table> </div> </p> </section> </section> <section id="CD012592-sec-0036"> <h3 class="title" id="CD012592-sec-0036">Methodological quality of included reviews</h3> <p>All the reviews met all AMSTAR criteria (<a href="./references#CD012592-bbs2-0070" title="SheaBJ , GrimshawJM , WellsGA , BoersM , AnderssonN , HamelC , et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Medical Research Methodology2007;7:10. [DOI: 10.1186/1471‐2288‐7‐10] ">Shea 2007</a>). They: </p> <p> <ol id="CD012592-list-0009"> <li> <p>had a priori design;</p> </li> <li> <p>performed duplicate study selection and data extraction;</p> </li> <li> <p>had a comprehensive literature search;</p> </li> <li> <p>used published and any unpublished studies, irrespective of language of publication, although not all review authors contacted companies or researchers for unpublished trial data; </p> </li> <li> <p>provided a list of included and excluded studies;</p> </li> <li> <p>provided characteristics of included studies;</p> </li> <li> <p>assessed and documented the scientific quality of the included studies;</p> </li> <li> <p>used the scientific quality of the included studies appropriately in formulating conclusions, because only studies with minimal risk of bias were included (a particular issue was trial size, but conclusions were not drawn from inadequate data sets, based on previously established criteria (<a href="./references#CD012592-bbs2-0049" title="MooreRA , GavaghanD , TramèrMR , CollinsSL , McQuayHJ . Size is everything ‐ large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209‐16. [DOI: 10.1016/S0304‐3959(98)00140‐7] ">Moore 1998</a>)); </p> </li> <li> <p>used appropriate methods to combine findings of studies and, importantly, provided analyses according to drug dose; and </p> </li> <li> <p>had an appropriate or adequate conflict of interest statement.</p> </li> </ol> </p> </section> <section id="CD012592-sec-0037"> <h3 class="title" id="CD012592-sec-0037">Effect of interventions</h3> <section id="CD012592-sec-0038"> <h4 class="title">Outcome: no worse than mild pain by 14 days</h4> <section id="CD012592-sec-0039"> <h5 class="title">1 Interventions for which Cochrane Reviews found no information</h5> <p>None of the reviews reported finding no information.</p> </section> <section id="CD012592-sec-0040"> <h5 class="title">2 Interventions for which Cochrane Reviews found inadequate information</h5> <p>We were unable to assess our main outcome of the number reporting no worse than mild pain in seven of the nine reviews (<a href="./references#CD012592-bbs2-0001" title="BaoYJ , HouW , KongXY , YangL , XiaJ , HuaBJ , et al. Hydromorphone for cancer pain. Cochrane Database of Systematic Reviews2016, Issue 10. [DOI: 10.1002/14651858.CD011108.pub2] ">Bao 2016</a>; <a href="./references#CD012592-bbs2-0003" title="NicholsonAB , WatsonGR , DerryS , WiffenPJ . Methadone for cancer pain. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.CD003971.pub4] ">Nicholson 2017</a>; <a href="./references#CD012592-bbs2-0004" title="Schmidt‐HansenM , BennettMI , ArnoldS , BromhamN , HilgartJS . Oxycodone for cancer‐related pain. Cochrane Database of Systematic Reviews2015, Issue 2. [DOI: 10.1002/14651858.CD003870.pub5] ">Schmidt‐Hansen 2015a</a>; <a href="./references#CD012592-bbs2-0005" title="Schmidt‐HansenM , BromhamN , TaubertM , ArnoldS , HilgartJS . Buprenorphine for treating cancer pain. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD009596.pub4] ">Schmidt‐Hansen 2015b</a>; <a href="./references#CD012592-bbs2-0006" title="StraubeC , DerryS , JacksonKC , WiffenPJ , BellRF , StrasselsS , et al. Codeine, alone and with paracetamol (acetaminophen), for cancer pain. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD006601.pub4] ">Straube 2014</a>; <a href="./references#CD012592-bbs2-0007" title="WiffenPJ , DerryS , NaessensK , BellRF . Oral tapentadol for cancer pain. Cochrane Database of Systematic Reviews2015, Issue 9. [DOI: 10.1002/14651858.CD011460.pub2] ">Wiffen 2015</a>; <a href="./references#CD012592-bbs2-0009" title="WiffenPJ , DerryS , MooreRA . Tramadol with or without paracetamol (acetaminophen) for cancer pain. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD012508] ">Wiffen 2017c</a>). These reviews contained fewer than 200 participants for assessment of the outcome of interest, but generally the outcome was not reported; most reported a GRADE assessment of very low quality evidence. </p> <p>Reported results were:</p> <p> <ul id="CD012592-list-0010"> <li> <p><a href="./references#CD012592-bbs2-0001" title="BaoYJ , HouW , KongXY , YangL , XiaJ , HuaBJ , et al. Hydromorphone for cancer pain. Cochrane Database of Systematic Reviews2016, Issue 10. [DOI: 10.1002/14651858.CD011108.pub2] ">Bao 2016</a>: Hydromorphone – outcome not determined or poorly reported in studies; very low quality. </p> </li> <li> <p><a href="./references#CD012592-bbs2-0003" title="NicholsonAB , WatsonGR , DerryS , WiffenPJ . Methadone for cancer pain. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.CD003971.pub4] ">Nicholson 2017</a>: Methadone – limited data poorly reported in studies; very low quality. </p> </li> <li> <p><a href="./references#CD012592-bbs2-0004" title="Schmidt‐HansenM , BennettMI , ArnoldS , BromhamN , HilgartJS . Oxycodone for cancer‐related pain. Cochrane Database of Systematic Reviews2015, Issue 2. [DOI: 10.1002/14651858.CD003870.pub5] ">Schmidt‐Hansen 2015a</a>: Oxycodone – scores given were average pain, but most participants appeared to have achieved no worse than mild pain; very low quality. </p> </li> <li> <p><a href="./references#CD012592-bbs2-0005" title="Schmidt‐HansenM , BromhamN , TaubertM , ArnoldS , HilgartJS . Buprenorphine for treating cancer pain. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD009596.pub4] ">Schmidt‐Hansen 2015b</a>: Buprenorphine – outcome not assessed; very low quality. </p> </li> <li> <p><a href="./references#CD012592-bbs2-0006" title="StraubeC , DerryS , JacksonKC , WiffenPJ , BellRF , StrasselsS , et al. Codeine, alone and with paracetamol (acetaminophen), for cancer pain. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD006601.pub4] ">Straube 2014</a>: Codeine – outcome not determined or poorly reported in studies; very low quality. </p> </li> <li> <p><a href="./references#CD012592-bbs2-0007" title="WiffenPJ , DerryS , NaessensK , BellRF . Oral tapentadol for cancer pain. Cochrane Database of Systematic Reviews2015, Issue 9. [DOI: 10.1002/14651858.CD011460.pub2] ">Wiffen 2015</a>: Tapentadol – outcome not determined or poorly reported in studies; no specific GRADE given. </p> </li> <li> <p><a href="./references#CD012592-bbs2-0009" title="WiffenPJ , DerryS , MooreRA . Tramadol with or without paracetamol (acetaminophen) for cancer pain. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD012508] ">Wiffen 2017c</a>: Tramadol – outcome not determined or poorly reported in studies; very low quality. </p> </li> </ul> </p> <p>We agree with the GRADE assessments of very low quality for those that made that assessment, and consider the tapentadol review also provides very low quality evidence. We downgraded the evidence because outcomes important to people with cancer pain were not reported, providing no useful evidence, irrespective of how many people in total were involved in studies included in the review, or how small the overall risk of bias. </p> </section> <section id="CD012592-sec-0041"> <h5 class="title">3 Interventions for which Cochrane Reviews found no evidence of effect or evidence of no effect </h5> <p>None of the reviews reported a null effect, although for the most part individual studies were comparing different opioids, or formulations, or doses, or dosing schedules, or a combination of these. The consequence of this was that studies or reviews had sufficient power only to determine that there was no difference within the confines of that comparison. </p> </section> <section id="CD012592-sec-0042"> <h5 class="title">4 Interventions for which Cochrane Reviews found evidence of effect, but where results were potentially subject to publication bias </h5> <p>We had planned to estimate the number of participants in unpublished studies of null effect required to increase an effect size to one that was clinically irrelevant (an NNT of 10 in a comparison with placebo). Where this number was less than 400 (equivalent to four studies with 100 participants per comparison, or 50 participants per group), we considered the results to be susceptible to publication bias and therefore unreliable and indicative of low‐quality evidence. </p> <p>In the event there were no analyses amenable to this estimation, and so we included no studies in this category. </p> </section> <section id="CD012592-sec-0043"> <h5 class="title">5 Interventions for which Cochrane Reviews found evidence of effect, where results were reliable and not subject to potential publication bias </h5> <p>Only two reviews reported on more than 200 events (<a href="./references#CD012592-bbs2-0002" title="HadleyG , DerryS , MooreRA , WiffenPJ . Transdermal fentanyl for cancer pain. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD010270.pub2] ">Hadley 2013</a>; <a href="./references#CD012592-bbs2-0008" title="WiffenPJ , WeeB , MooreRA . Oral morphine for cancer pain. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003868.pub4] ">Wiffen 2016</a>). Both showed that when doses were titrated to effect, 96% of participants achieved no worse than mild pain. </p> <p> <ul id="CD012592-list-0011"> <li> <p><a href="./references#CD012592-bbs2-0002" title="HadleyG , DerryS , MooreRA , WiffenPJ . Transdermal fentanyl for cancer pain. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD010270.pub2] ">Hadley 2013</a>: Tansdermal fentanyl – 461/479 (96%); no GRADE assessment given. </p> </li> <li> <p><a href="./references#CD012592-bbs2-0008" title="WiffenPJ , WeeB , MooreRA . Oral morphine for cancer pain. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003868.pub4] ">Wiffen 2016</a>: Oral morphine – 362/377 (96%); no GRADE assessment given. </p> </li> </ul> </p> <p>We assessed this evidence as moderate quality, downgraded because of a number of minor methodological issues, including the lack of double‐blinding in some studies. </p> </section> </section> <section id="CD012592-sec-0044"> <h4 class="title">Outcome: patient‐reported global impression of change (PGIC)</h4> <p>Five reviews included PGIC as an outcome (<a href="./references#CD012592-bbs2-0002" title="HadleyG , DerryS , MooreRA , WiffenPJ . Transdermal fentanyl for cancer pain. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD010270.pub2] ">Hadley 2013</a>; <a href="./references#CD012592-bbs2-0005" title="Schmidt‐HansenM , BromhamN , TaubertM , ArnoldS , HilgartJS . Buprenorphine for treating cancer pain. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD009596.pub4] ">Schmidt‐Hansen 2015b</a>; <a href="./references#CD012592-bbs2-0006" title="StraubeC , DerryS , JacksonKC , WiffenPJ , BellRF , StrasselsS , et al. Codeine, alone and with paracetamol (acetaminophen), for cancer pain. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD006601.pub4] ">Straube 2014</a>; <a href="./references#CD012592-bbs2-0007" title="WiffenPJ , DerryS , NaessensK , BellRF . Oral tapentadol for cancer pain. Cochrane Database of Systematic Reviews2015, Issue 9. [DOI: 10.1002/14651858.CD011460.pub2] ">Wiffen 2015</a>; <a href="./references#CD012592-bbs2-0009" title="WiffenPJ , DerryS , MooreRA . Tramadol with or without paracetamol (acetaminophen) for cancer pain. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD012508] ">Wiffen 2017c</a>). None was able to determine this outcome from any of the included studies. </p> <p>We assessed this evidence as very low quality because there was no information.</p> </section> <section id="CD012592-sec-0045"> <h4 class="title">Outcome: withdrawals due to adverse events</h4> <p>Summary table B shows the results reported for withdrawals due to adverse events and the GRADE assessments. Four reviews were unable to report on this outcome due to it being poorly or not reported in included studies (<a href="./references#CD012592-bbs2-0001" title="BaoYJ , HouW , KongXY , YangL , XiaJ , HuaBJ , et al. Hydromorphone for cancer pain. Cochrane Database of Systematic Reviews2016, Issue 10. [DOI: 10.1002/14651858.CD011108.pub2] ">Bao 2016</a>; <a href="./references#CD012592-bbs2-0002" title="HadleyG , DerryS , MooreRA , WiffenPJ . Transdermal fentanyl for cancer pain. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD010270.pub2] ">Hadley 2013</a>; <a href="./references#CD012592-bbs2-0006" title="StraubeC , DerryS , JacksonKC , WiffenPJ , BellRF , StrasselsS , et al. Codeine, alone and with paracetamol (acetaminophen), for cancer pain. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD006601.pub4] ">Straube 2014</a>; <a href="./references#CD012592-bbs2-0009" title="WiffenPJ , DerryS , MooreRA . Tramadol with or without paracetamol (acetaminophen) for cancer pain. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD012508] ">Wiffen 2017c</a>). </p> <p>Five of the reviews reported on withdrawals due to adverse events from at least some of the studies they included (<a href="./references#CD012592-bbs2-0003" title="NicholsonAB , WatsonGR , DerryS , WiffenPJ . Methadone for cancer pain. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.CD003971.pub4] ">Nicholson 2017</a>; <a href="./references#CD012592-bbs2-0004" title="Schmidt‐HansenM , BennettMI , ArnoldS , BromhamN , HilgartJS . Oxycodone for cancer‐related pain. Cochrane Database of Systematic Reviews2015, Issue 2. [DOI: 10.1002/14651858.CD003870.pub5] ">Schmidt‐Hansen 2015a</a>; <a href="./references#CD012592-bbs2-0005" title="Schmidt‐HansenM , BromhamN , TaubertM , ArnoldS , HilgartJS . Buprenorphine for treating cancer pain. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD009596.pub4] ">Schmidt‐Hansen 2015b</a>; <a href="./references#CD012592-bbs2-0007" title="WiffenPJ , DerryS , NaessensK , BellRF . Oral tapentadol for cancer pain. Cochrane Database of Systematic Reviews2015, Issue 9. [DOI: 10.1002/14651858.CD011460.pub2] ">Wiffen 2015</a>; <a href="./references#CD012592-bbs2-0008" title="WiffenPJ , WeeB , MooreRA . Oral morphine for cancer pain. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003868.pub4] ">Wiffen 2016</a>). Adverse event withdrawal rates in the two largest data sets were 19% (oral oxycodone) and 7% (oral morphine), based on 513 and 154 withdrawals respectively. The other three estimates were 6% to 13%, based on 12 to 52 withdrawals. Despite the low numbers of events in some reviews, there was a degree of consistency between the reviews. </p> <p>GRADE estimates were of very low quality for methadone, oxycodone, and buprenorphine, and no specific GRADE estimate was made for tapentadol or morphine. We assessed this evidence as very low quality because of poor reporting of the outcome in most cases, and usually small numbers of events. </p> <section id="CD012592-sec-0046"> <h5 class="title">Summary table B: summary of available results on the outcome of withdrawals due to adverse events </h5> <p> <div class="table" id="CD012592-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reference</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Opioid</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Active</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>GRADE</b> </p> <p><b>(review reported)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0001" title="BaoYJ , HouW , KongXY , YangL , XiaJ , HuaBJ , et al. Hydromorphone for cancer pain. Cochrane Database of Systematic Reviews2016, Issue 10. [DOI: 10.1002/14651858.CD011108.pub2] ">Bao 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydromorphone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not determined – poorly</p> <p>reported in studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0002" title="HadleyG , DerryS , MooreRA , WiffenPJ . Transdermal fentanyl for cancer pain. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD010270.pub2] ">Hadley 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fentanyl</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not determined – poorly</p> <p>reported in studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No specific GRADE given</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0003" title="NicholsonAB , WatsonGR , DerryS , WiffenPJ . Methadone for cancer pain. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.CD003971.pub4] ">Nicholson 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methadone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/202 (6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0004" title="Schmidt‐HansenM , BennettMI , ArnoldS , BromhamN , HilgartJS . Oxycodone for cancer‐related pain. Cochrane Database of Systematic Reviews2015, Issue 2. [DOI: 10.1002/14651858.CD003870.pub5] ">Schmidt‐Hansen 2015a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxycodone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>513/2648 (19%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0005" title="Schmidt‐HansenM , BromhamN , TaubertM , ArnoldS , HilgartJS . Buprenorphine for treating cancer pain. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD009596.pub4] ">Schmidt‐Hansen 2015b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Buprenorphine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52/443 (12%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0006" title="StraubeC , DerryS , JacksonKC , WiffenPJ , BellRF , StrasselsS , et al. Codeine, alone and with paracetamol (acetaminophen), for cancer pain. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD006601.pub4] ">Straube 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Codeine with or without paracetamol</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not determined – poorly</p> <p>reported in studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0007" title="WiffenPJ , DerryS , NaessensK , BellRF . Oral tapentadol for cancer pain. Cochrane Database of Systematic Reviews2015, Issue 9. [DOI: 10.1002/14651858.CD011460.pub2] ">Wiffen 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tapentadol</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/168 (13%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No specific GRADE given</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0008" title="WiffenPJ , WeeB , MooreRA . Oral morphine for cancer pain. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003868.pub4] ">Wiffen 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Morphine instant release and modified release</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>154/2162 (7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No specific GRADE given</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0009" title="WiffenPJ , DerryS , MooreRA . Tramadol with or without paracetamol (acetaminophen) for cancer pain. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD012508] ">Wiffen 2017c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tramadol with or without paracetamol</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not determined – poorly</p> <p>reported in studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> </tr> </tbody> </table> </div> </p> </section> </section> <section id="CD012592-sec-0047"> <h4 class="title">Outcome: participants with at least one adverse event</h4> <p>Summary table C shows the results reported for participants with at least one adverse event and the GRADE assessments. Six reviews were unable to report on this outcome due to it being poorly or not reported in studies (<a href="./references#CD012592-bbs2-0001" title="BaoYJ , HouW , KongXY , YangL , XiaJ , HuaBJ , et al. Hydromorphone for cancer pain. Cochrane Database of Systematic Reviews2016, Issue 10. [DOI: 10.1002/14651858.CD011108.pub2] ">Bao 2016</a>; <a href="./references#CD012592-bbs2-0002" title="HadleyG , DerryS , MooreRA , WiffenPJ . Transdermal fentanyl for cancer pain. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD010270.pub2] ">Hadley 2013</a>; <a href="./references#CD012592-bbs2-0003" title="NicholsonAB , WatsonGR , DerryS , WiffenPJ . Methadone for cancer pain. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.CD003971.pub4] ">Nicholson 2017</a>; <a href="./references#CD012592-bbs2-0004" title="Schmidt‐HansenM , BennettMI , ArnoldS , BromhamN , HilgartJS . Oxycodone for cancer‐related pain. Cochrane Database of Systematic Reviews2015, Issue 2. [DOI: 10.1002/14651858.CD003870.pub5] ">Schmidt‐Hansen 2015a</a>; <a href="./references#CD012592-bbs2-0006" title="StraubeC , DerryS , JacksonKC , WiffenPJ , BellRF , StrasselsS , et al. Codeine, alone and with paracetamol (acetaminophen), for cancer pain. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD006601.pub4] ">Straube 2014</a>; <a href="./references#CD012592-bbs2-0008" title="WiffenPJ , WeeB , MooreRA . Oral morphine for cancer pain. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003868.pub4] ">Wiffen 2016</a>). </p> <p>Three of the reviews reported on participants with at least one adverse event from at least some of the studies they included (<a href="./references#CD012592-bbs2-0005" title="Schmidt‐HansenM , BromhamN , TaubertM , ArnoldS , HilgartJS . Buprenorphine for treating cancer pain. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD009596.pub4] ">Schmidt‐Hansen 2015b</a>; <a href="./references#CD012592-bbs2-0007" title="WiffenPJ , DerryS , NaessensK , BellRF . Oral tapentadol for cancer pain. Cochrane Database of Systematic Reviews2015, Issue 9. [DOI: 10.1002/14651858.CD011460.pub2] ">Wiffen 2015</a>; <a href="./references#CD012592-bbs2-0009" title="WiffenPJ , DerryS , MooreRA . Tramadol with or without paracetamol (acetaminophen) for cancer pain. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD012508] ">Wiffen 2017c</a>). There was little consistency in the proportion of participants reporting any adverse event, with rates above 50% for buprenorphine and tapentadol, but as low as 11% with tramadol plus paracetamol. </p> <p>GRADE estimates were of very low quality apart from fentanyl, tapentadol, and morphine, for which no specific GRADE estimate was made. We assessed this evidence as very low quality because of poor reporting and small numbers of events. </p> </section> <section id="CD012592-sec-0048"> <h4 class="title">Summary table C: participants reporting at least one adverse event</h4> <p> <div class="table" id="CD012592-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reference</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Opioid</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number with at least one adverse event (per cent)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>GRADE</b> </p> <p><b>(review reported)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0001" title="BaoYJ , HouW , KongXY , YangL , XiaJ , HuaBJ , et al. Hydromorphone for cancer pain. Cochrane Database of Systematic Reviews2016, Issue 10. [DOI: 10.1002/14651858.CD011108.pub2] ">Bao 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydromorphone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Meaningful analysis not possible due to poor reporting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0002" title="HadleyG , DerryS , MooreRA , WiffenPJ . Transdermal fentanyl for cancer pain. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD010270.pub2] ">Hadley 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fentanyl</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Meaningful analysis not possible due to poor reporting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No specific GRADE given</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0003" title="NicholsonAB , WatsonGR , DerryS , WiffenPJ . Methadone for cancer pain. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.CD003971.pub4] ">Nicholson 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methadone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Meaningful analysis not possible due to poor reporting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0004" title="Schmidt‐HansenM , BennettMI , ArnoldS , BromhamN , HilgartJS . Oxycodone for cancer‐related pain. Cochrane Database of Systematic Reviews2015, Issue 2. [DOI: 10.1002/14651858.CD003870.pub5] ">Schmidt‐Hansen 2015a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxycodone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Meaningful analysis not possible due to poor reporting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0005" title="Schmidt‐HansenM , BromhamN , TaubertM , ArnoldS , HilgartJS . Buprenorphine for treating cancer pain. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD009596.pub4] ">Schmidt‐Hansen 2015b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Buprenorphine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152/264 (57%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0006" title="StraubeC , DerryS , JacksonKC , WiffenPJ , BellRF , StrasselsS , et al. Codeine, alone and with paracetamol (acetaminophen), for cancer pain. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD006601.pub4] ">Straube 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Codeine with or without paracetamol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Meaningful analysis not possible due to poor reporting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0007" title="WiffenPJ , DerryS , NaessensK , BellRF . Oral tapentadol for cancer pain. Cochrane Database of Systematic Reviews2015, Issue 9. [DOI: 10.1002/14651858.CD011460.pub2] ">Wiffen 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tapentadol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>297/386 (77%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No specific GRADE given</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0008" title="WiffenPJ , WeeB , MooreRA . Oral morphine for cancer pain. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003868.pub4] ">Wiffen 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Morphine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Meaningful analysis not possible due to poor reporting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No specific GRADE given</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0009" title="WiffenPJ , DerryS , MooreRA . Tramadol with or without paracetamol (acetaminophen) for cancer pain. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD012508] ">Wiffen 2017c</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tramadol with or without paracetamol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29/267 (11%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> </tr> </tbody> </table> </div> </p> </section> <section id="CD012592-sec-0049"> <h4 class="title">Other outcomes</h4> <p>Secondary outcomes of withdrawals due to lack of efficacy or participants experiencing any serious adverse event were not reported with any consistency (see Table D). Specific adverse events, such as thirst, reduced appetite, somnolence and dizziness, are reported in a separate review (<a href="./references#CD012592-bbs2-0010" title="WiffenPJ , DerryS , MooreRA . Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain. Cochrane Database of Systematic Reviews2014, Issue 5. [DOI: 10.1002/14651858.CD011056.pub2] ">Wiffen 2014</a>), and we found no additional information that would require an update of that review. </p> </section> <section id="CD012592-sec-0050"> <h4 class="title">Summary table D: Serious adverse events and death</h4> <p> <div class="table" id="CD012592-tblf-0004"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reference</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Opioid</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Deaths</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0001" title="BaoYJ , HouW , KongXY , YangL , XiaJ , HuaBJ , et al. Hydromorphone for cancer pain. Cochrane Database of Systematic Reviews2016, Issue 10. [DOI: 10.1002/14651858.CD011108.pub2] ">Bao 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hydromorphone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not determined – poorly</p> <p>reported in studies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No deaths in one study of 99 participants</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0002" title="HadleyG , DerryS , MooreRA , WiffenPJ . Transdermal fentanyl for cancer pain. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD010270.pub2] ">Hadley 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fentanyl</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not determined – poorly</p> <p>reported in studies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 deaths in 1066 participants</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0003" title="NicholsonAB , WatsonGR , DerryS , WiffenPJ . Methadone for cancer pain. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.CD003971.pub4] ">Nicholson 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methadone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/202 (6%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death uncommon, apart from one study</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0004" title="Schmidt‐HansenM , BennettMI , ArnoldS , BromhamN , HilgartJS . Oxycodone for cancer‐related pain. Cochrane Database of Systematic Reviews2015, Issue 2. [DOI: 10.1002/14651858.CD003870.pub5] ">Schmidt‐Hansen 2015a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxycodone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not determined – poorly</p> <p>reported in studies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not determined – poorly</p> <p>reported in studies</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0005" title="Schmidt‐HansenM , BromhamN , TaubertM , ArnoldS , HilgartJS . Buprenorphine for treating cancer pain. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD009596.pub4] ">Schmidt‐Hansen 2015b</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Buprenorphine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not determined – poorly</p> <p>reported in studies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not determined – poorly</p> <p>reported in studies</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0006" title="StraubeC , DerryS , JacksonKC , WiffenPJ , BellRF , StrasselsS , et al. Codeine, alone and with paracetamol (acetaminophen), for cancer pain. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD006601.pub4] ">Straube 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Codeine with or without paracetamol</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not determined – poorly</p> <p>reported in studies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not determined – poorly</p> <p>reported in studies</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0007" title="WiffenPJ , DerryS , NaessensK , BellRF . Oral tapentadol for cancer pain. Cochrane Database of Systematic Reviews2015, Issue 9. [DOI: 10.1002/14651858.CD011460.pub2] ">Wiffen 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tapentadol</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/168 (13%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 deaths in one study of 168 participants</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0008" title="WiffenPJ , WeeB , MooreRA . Oral morphine for cancer pain. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003868.pub4] ">Wiffen 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Morphine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not determined – poorly</p> <p>reported in studies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not determined – poorly</p> <p>reported in studies</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012592-bbs2-0009" title="WiffenPJ , DerryS , MooreRA . Tramadol with or without paracetamol (acetaminophen) for cancer pain. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD012508] ">Wiffen 2017c</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tramadol with or without paracetamol</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not determined – poorly</p> <p>reported in studies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 deaths in 280 participants</p> </td> </tr> </tbody> </table> </div> </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012592-sec-0051" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012592-sec-0051"></div> <section id="CD012592-sec-0052"> <h3 class="title" id="CD012592-sec-0052">Summary of main results</h3> <p>Nine Cochrane Reviews examined opioids administered by various routes for treating typically moderate to severe cancer‐related pain across a range of malignancies. These nine reviews had a maximum of 152 included studies and 13,524 included participants. Particular opioids investigated were buprenorphine, codeine with or without paracetamol, fentanyl, hydromorphone, methadone, morphine, oxycodone, tapentadol, and tramadol with or without paracetamol, covering the range of opioids commonly prescribed for cancer pain, at least in England (<a href="./references#CD012592-bbs2-0061" title="Prescribing &amp; Medicines Team. Prescription Cost Analysis England 2016. Health and Social Care Information Centre2017 (April). [ISBN: 978‐1‐78386‐680‐9] ">PCA 2016</a>). </p> <p>The primary outcomes of interest in this overview were the proportion of participants reporting no worse than mild pain on treatment by 14 days after start of treatment, patient global impression of change (PGIC) of much or very much improved, and withdrawals due to adverse events. This would then provide evidence to help decisions in clinical practice (<a href="#CD012592-fig-0001">Figure 1</a>). There was limited information on these outcomes. </p> <p>Only the reviews of oral morphine and transdermal fentanyl reported the important outcome for people with cancer pain of having only mild or no pain within a reasonable time (14 days) after treatment started (<a href="./references#CD012592-bbs2-0052" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut‐offs ‐ 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400‐12. [DOI: 10.1111/anae.12148] ">Moore 2013</a>). But these two reviews demonstrated that 96% of participants achieved this outcome in a combined total of 856 participants (<a href="./references#CD012592-bbs2-0002" title="HadleyG , DerryS , MooreRA , WiffenPJ . Transdermal fentanyl for cancer pain. Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD010270.pub2] ">Hadley 2013</a>; <a href="./references#CD012592-bbs2-0008" title="WiffenPJ , WeeB , MooreRA . Oral morphine for cancer pain. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD003868.pub4] ">Wiffen 2016</a>). Another review of oxycodone reported average pain scores that were so low that most people would have had no worse than mild pain (<a href="./references#CD012592-bbs2-0004" title="Schmidt‐HansenM , BennettMI , ArnoldS , BromhamN , HilgartJS . Oxycodone for cancer‐related pain. Cochrane Database of Systematic Reviews2015, Issue 2. [DOI: 10.1002/14651858.CD003870.pub5] ">Schmidt‐Hansen 2015a</a>). There were no results for the PGIC outcome, and inconsistent results for the number of adverse event withdrawals, although these were always below 20%. The number of participants experiencing any adverse event was inconsistently reported, and when reported occurred inconsistently, with event rates between 11% and 77%. </p> <p>The WHO ladder has strong opioids as the top rung of the ladder, and the evidence we have supports that position. Systematic reviews of surveys and observational studies have investigated the effectiveness of the WHO ladder and, despite using different inclusion criteria and outcomes, they tend to conclude that the range of people with cancer pain achieving 'adequate' analgesia ranges between 22% and 100% at the extremes (<a href="./references#CD012592-bbs2-0012" title="Azevedo São Leão FerreiraK , KimuraM , Jacobsen TeixeiraM . The WHO analgesic ladder for cancer pain control, twenty years of use. How much pain relief does one get from using it?. Supportive Care in Cancer2006;14(11):1086‐93. [DOI: 10.1007/s00520‐006‐0086‐x] ">Azevedo São Leão Ferreira 2006</a>; <a href="./references#CD012592-bbs2-0017" title="CarlsonCL . Effectiveness of the World Health Organization cancer pain relief guidelines: an integrative review. Journal of Pain Research2016;9:515‐34. [DOI: 10.2147/JPR.S97759] ">Carlson 2016</a>; <a href="./references#CD012592-bbs2-0023" title="DeandreaS , MontanariM , MojaL , ApoloneG . Prevalence of undertreatment in cancer pain. A review of published literature. Annals of Oncology2008;19(12):1985‐91. [DOI: 10.1093/annonc/mdn419] ">Deandrea 2008</a>; <a href="./references#CD012592-bbs2-0043" title="JadadAR , BrowmanGP . The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. JAMA1995;274(23):1870‐3. [DOI: 10.1001/jama.1995.03530230056031] ">Jadad 1995</a>). Many individual studies show that fewer than 80% of people with cancer pain have satisfactory pain relief using the WHO ladder, which is less than the theoretical 96% or more that might be expected from the best results from oral morphine and transdermal fentanyl. The reasons for this difference between results in clinical practice and clinical trials is not known, but may include only selected populations being involved in clinical trials, and those trials often reporting a completer analysis and inadequately handling data from participants who withdraw during treatment. </p> </section> <section id="CD012592-sec-0053"> <h3 class="title" id="CD012592-sec-0053">Overall completeness and applicability of evidence</h3> <p>This overview highlights the paucity of our knowledge about the effectiveness of opioids for cancer pain. There is, of course, an understanding that most opioids are effective in managing cancer pain providing the dose is titrated to effect (with the exception of codeine and probably tramadol), but we know little from this overview about whether there are any differences in efficacy, adverse events, or effectiveness. </p> <p>Studies in the reviews were typically designed to demonstrate no difference between opioids, or that a newer opioid or changed formulation may have some benefits (such as longer duration of effect, or ease of use) while maintaining a similar efficacy to a standard opioid preparation at the doses used. This led to a large number of studies examining what amounted to different drugs, and limited the possibility of any comparative analysis. What was left was essentially an analysis of randomised cohorts showing little difference between, for example, different oral morphine preparations or different transdermal fentanyl preparations. </p> <p>This is not without some practical importance because it suggests that, as long as the expected pain relief follows at sensible doses, at least some opioids can be chosen for use based on convenience to the provider and the person with cancer pain, or the availability, or the cost. We can at least be sure that some, perhaps most, people treated will have adverse events; and some, probably a few, will find these intolerable and will discontinue treatment with one opioid and move to an alternative opioid. </p> <p>It remains disappointing that more cannot be said, despite this moderately large number of studies and participants. </p> </section> <section id="CD012592-sec-0054"> <h3 class="title" id="CD012592-sec-0054">Quality of the evidence</h3> <p>Many, if not most, of the studies in the individual reviews had one or more elements that indicated a high risk of bias. This was often a lack of blinding, and restricting inclusion of studies to those convincingly double blind would have resulted in a significant reduction in the number of included studies. Stringent exclusion of studies with risk of bias items known to have potentially large positive bias effects in pain studies would have meant a major reduction in the number of included studies, even for some of the most recently introduced opioids. </p> <p>Small size is increasingly recognised as being a major issue in studies and reviews (<a href="./references#CD012592-bbs2-0032" title="FanelliD , CostasR , IoannidisJP . Meta‐assessment of bias in science. Proceedings of the National Academy of Sciences of the USA 2017 Mar 20 [Epub ahead of print];114(14):3714‐9. [DOI: 10.1073/pnas.1618569114] ">Fanelli 2017</a>; <a href="./references#CD012592-bbs2-0049" title="MooreRA , GavaghanD , TramèrMR , CollinsSL , McQuayHJ . Size is everything ‐ large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209‐16. [DOI: 10.1016/S0304‐3959(98)00140‐7] ">Moore 1998</a>; <a href="./references#CD012592-bbs2-0056" title="NguyenTL , CollinsGS , LamyA , DevereauxPJ , DaurèsJP , LandaisP , et al. Simple randomization did not protect against bias in smaller trials. Journal of Clinical Epidemiology 2017 Feb 29 [Epub ahead of print];84:105‐13. [DOI: 10.1016/j.jclinepi.2017.02.010] ">Nguyen 2017</a>; <a href="./references#CD012592-bbs2-0074" title="ThorlundK , ImbergerG , WalshM , ChuR , GluudC , WetterslevJ , et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta‐analysis‐‐a simulation study. PLoS One2011;6(10):e25491. [DOI: 10.1371/journal.pone.0025491] ">Thorlund 2011</a>), and some Cochrane Reviews have been criticised for making conclusive assessments of evidence based on inadequate information, largely or wholly from small underpowered studies (<a href="./references#CD012592-bbs2-0011" title="AlBalawiZ , McAlisterFA , ThorlundK , WongM , WetterslevJ . Random error in cardiovascular meta‐analyses: how common are false positive and false negative results?. International Journal of Cardiology2013;168(2):1102‐7. [DOI: 10.1016/j.ijcard.2012.11.048] ">AlBalawi 2013</a>; <a href="./references#CD012592-bbs2-0015" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta‐analyses may be inconclusive ‐ trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International Journal of Epidemiology2009;38(1):287‐98. [DOI: 10.1093/ije/dyn188] ">Brok 2009</a>; <a href="./references#CD012592-bbs2-0067" title="RobertsI , KerK , EdwardsP , BeecherD , MannoD , SydenhamE . The knowledge system underpinning healthcare is not fit for purpose and must change. BMJ2015;350:h2463. [DOI: 10.1136/bmj.h2463] ">Roberts 2015</a>; <a href="./references#CD012592-bbs2-0076" title="TurnerRM , BirdSM , HigginsJP . The impact of study size on meta‐analyses: examination of underpowered studies in Cochrane reviews. PLOS One2013;8(3):e59202. [DOI: 10.1371/journal.pone.0059202] ">Turner 2013</a>). The average size of studies in the individual reviews was below 100 participants for codeine, buprenorphine, methadone, morphine, and tramadol, between 100 and 200 for hydromorphone, fentanyl, and oxycodone, and above 200 only for tapentadol. Many individual studies may therefore also have been at risk of bias because of the small size. </p> <p>Some individual trial sizes were disappointingly low — as low as 11 participants at one extreme. Recent studies for the new opioid tapentadol were more realistic in size. </p> <p>Reporting of adverse events was poor and inconsistent, with underpowered studies and little or no information about how the data were collected. This is disappointing, since adverse events are common with opioids, and treatment choices are frequently driven by issues of tolerability. </p> <p>The majority of studies were sponsored by pharmaceutical companies and designed to show non‐inferiority to instant‐release morphine for modified‐release morphine products, or to show non‐inferiority (particularly to morphine) of newer potent opioids. This might be helpful for licensing and marketing purposes for pharmaceutical companies, but is of limited value in patient care. As far as we can tell there has been little investment in clinical trials from government or charities, despite the large sums spent on treating cancer pain. </p> <p>Where we were able to obtain the GRADE assessment of quality of the evidence from the included reviews, it was judged to be very low. We agreed with these assessments, principally because of poor reporting, often small numbers of events, and high risk of bias on one or more items. </p> <p>Very low quality means that we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </section> <section id="CD012592-sec-0055"> <h3 class="title" id="CD012592-sec-0055">Potential biases in the overview process</h3> <p>We are unaware of any biases in the review process. One potential bias is the overlap between authors of the overview and of some of the individual reviews. This has been addressed by having other experienced authors for the overview. </p> </section> <section id="CD012592-sec-0056"> <h3 class="title" id="CD012592-sec-0056">Agreements and disagreements with other studies or reviews</h3> <p>We are not aware of any other overviews of opioids for cancer pain for comparison.</p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012592-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012592.pub2/media/CDSR/CD012592/urn:x-wiley:14651858:media:CD012592:CD012592-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012592.pub2/media/CDSR/CD012592/image_t/tCD012592-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD012592-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012592.pub2/media/CDSR/CD012592/image_n/nCD012592-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012592.pub2/full#CD012592-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012592.pub2/media/CDSR/CD012592/image_n/nCD012592-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012592.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012592-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012592-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD012592-note-0004">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD012592-note-0001">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD012592-note-0002">Polski</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"/> </img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br/> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012592\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012592\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012592\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012592\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012592\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012592\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012592\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012592\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012592\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012592\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012592\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012592\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012592\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012592\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012592\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012592\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012592\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012592\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=qy4lqFNF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012592.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012592.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012592.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012592.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012592.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728856931"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012592.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728856934"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012592.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eceb69c989368',t:'MTc0MDcyODg1Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 